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Several orthopoxviruses (OPV) and Borna disease virus (BDV) are enveloped, 
zoonotic viruses with a wide geographical distribution. OPV antibodies cross-react, 
and former smallpox vaccination has therefore protected human populations from 
another OPV infection, rodent-borne cowpox virus (CPXV). Cowpox in humans and 
cats usually manifests as a mild, self-limiting dermatitis and constitutional symptoms, 
but it can be severe and even life-threatening in the immunocompromised. Classical 
Borna disease is a progressive meningoencephalomyelitis in horses and sheep known 
in central Europe for centuries. Nowadays the virus or its close relative infects humans 
and also several other species in central Europe and elsewhere, but the existence of 
human Borna disease with its suspected neuropsychiatric symptoms is controversial. 
The epidemiology of BDV is largely unknown, and the present situation is even more 
intriguing following the recent detection of several-million-year-old, endogenized 
BDV genes in primate and various other vertebrate genomes.
The aims of this study were to elucidate the importance of CPXV and BDV in 
Finland and in possible host species, and particularly to 1) establish relevant methods 
for the detection of CPXV and other OPVs as well as BDV in Finland, 2) determine 
whether CPXV and BDV exist in Finland, 3) discover how common OPV immunity 
is in different age groups in Finland, 4) characterize possible disease cases and clarify 
their epidemiological context, 5) establish the hosts and possible reservoir species of 
these viruses and their geographical distribution in wild rodents, and 6) elucidate the 
infection kinetics of BDV in the bank vole.
An indirect immunofluorescence assay and avidity measurement were established for 
the detection, timing and verification of OPV or BDV antibodies in thousands of 
blood samples from humans, horses, ruminants, lynxes, gallinaceous birds, dogs, cats 
and rodents. The mostly vaccine-derived OPV seroprevalence was found to decrease 
gradually according to the year of birth of the sampled human subjects from 100% 
to 10% in those born after 1977. On the other hand, OPV antibodies indicating 
natural contact with CPXV or other OPVs were commonly found in domestic and 
wild animals: the horse, cow, lynx, dog, cat and, with a prevalence occasionally even 
as high as 92%, in wild rodents, including some previously undetected species and 
new regions. Antibodies to BDV were detected in humans, horses, a dog, cats, and 
for the first time in wild rodents, such as bank voles (Myodes glareolus). Because of the 
controversy within the human Borna disease field, extra verification methods were 
established for BDV antibody findings: recombinant nucleocapsid and phosphoproteins 
were produced in Escherichia coli and in a baculovirus system, and peptide arrays were 
additionally applied. with these verification assays, Finnish human, equine, feline 
and rodent BDV infections were confirmed. Taken together, wide host spectra were 
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evident for both OPV and BDV infections based on the antibody findings, and OPV 
infections were found to be geographically broadly distributed. 
PCR amplification methods were utilised for hundreds of blood and tissue samples. 
The methods included conventional, nested and real-time PCRs with or without 
the reverse transcription step and detecting four or two genes of OPVs and BDV, 
respectively. OPV DNA could be amplified from two human patients and three 
bank voles, whereas no BDV RNA was detected in naturally infected individuals. 
Based on the phylogenetic analyses, the Finnish OPV sequences were closely related 
although not identical to a Russian CPXV isolate, and clearly different from other 
CPXV strains. Moreover, the Finnish sequences only equalled each other, but the 
short amplicons obtained from German rodents were identical to monkeypox virus, in 
addition to German CPXV variants. This reflects the close relationship of all OPVs. In 
summary, RNA of the Finnish BDV variant could not be detected with the available 
PCR methods, but OPV DNA infrequently could. The OPV species infecting the 
patients of this study was proven to be CPXV, which is most probably also responsible 
for the rodent infections.
Multiple cell lines and some newborn rodents were utilised in the isolation of CPXV 
and BDV from patient and wildlife samples. CPXV could be isolated from a child with 
severe, generalised cowpox. BDV isolation attempts from rodents were unsuccessful in 
this study. However, in parallel studies, a transient BDV infection of cells inoculated 
with equine brain material was detected, and BDV antigens discovered in archival 
animal brains using established immunohistology. Thus, based on several independent 
methods, both CPXV and BDV (or a closely related agent) were shown to be present 
in Finland.
Bank voles could be productively infected with BDV. This experimental infection did 
not result in notable pathological findings or symptoms, despite the intense spread 
of the virus in the central and peripheral nervous system. Infected voles commonly 
excreted the virus in urine and faeces, which emphasises their possible role as a BDV 
reservoir. Moreover, BDV RNA was regularly reverse transcribed into DNA in bank 
voles, which was detected by amplifying DNA by PCR without reverse transcription, 
and verified with nuclease treatments. This finding indicates that BDV genes could 
be endogenized during an acute infection. Although further transmission studies are 
needed, this experimental infection demonstrated that the bank vole can function as 
a potential BDV reservoir. 
In summary, multiple methods were established and applied in large panels to detect 
two zoonoses novel to Finland: cowpox virus and Borna disease virus. Moreover, 
new information was obtained on their geographical distribution, host spectrum, 
epidemiology and infection kinetics.
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AIX avidity index = (antibody titre with urea wash) / (antibody titre 
without urea wash) x 100%
BD Borna disease
BDV Borna disease virus
bp base pairs




CNS central nervous system
CPXV cowpox virus
CSF cerebrospinal fluid
Ct cycle threshold in real-time PCR
dpi days post infection
EBL endogenous Borna-like element
EBLN endogenous Borna-like N element
ECTV ectromelia virus
ELISA enzyme-linked immunosorbent assay
FCS foetal calf serum
ffu focus-forming unit
HA haemagglutinin




IFA indirect immunofluorescence assay
Ig immunoglobulin
kb kilobase, 1000 base pairs
kDa kilodalton








PCR polymerase chain reaction
p.i. post infection
REB rabbit embryonic brain cells
RNP ribonucleoprotein
RT reverse transcriptase / reverse transcription
Sf9 Spodoptera frugiperda insect́ s cells
VACV vaccinia virus
VARV variola / smallpox virus
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1. introDuction
Any infection or disease that is naturally transmissible between vertebrate animals 
and humans is, according to the definition of the world Health Organization, 
classified as a zoonosis (3). More than 60% of all human diseases and as many as 80% 
of emerging ones are zoonoses (66). Of the emerging zoonotic pathogens, 58% infect 
ungulates, 51% carnivores, and 34% rodents emphasising the utmost importance of 
collaboration between veterinary, medical and wildlife sciences in the detection and 
battle against these threats. Viruses are the most ubiquitous emerging pathogens, 
as they cause about half of emerging diseases in humans, domestic livestock and 
domestic carnivores (66).
This thesis addresses to two zoonotic, probably emerging viruses: cowpox virus 
(CPXV) and Borna disease virus (BDV). Both are well known veterinary pathogens 
that, in addition to ungulates and carnivores, also infect humans and have their proven 
(CPXV) or suspected (BDV) host among wild rodents (63, 299). CPXV infection in 
domestic animals (and especially cats, despite the name) and humans leads to cowpox, 
the signs of which vary from painful dermatitis to severe, even lethal systemic infection 
(28). Animal Borna disease has classically been described as a chronic, progressive 
meningoencephalomyelitis including both neurological and behavioural symptoms in 
horses and sheep (92). During recent decades, milder manifestations and a wider host 
range have also been seen (34, 196). In humans, numerous neuropsychiatric entities 
have been associated with BDV infection, but the causative role is controversial (262, 
266). This view has become even more intriguing since the recent observation of BDV 
gene endogenization in vertebrate genomes (27, 155).
CPXV belongs to orthopoxviruses (OPV) together with other related, cross-reactive 
and cross-protective viruses such as vaccinia virus (VACV) and variola virus (VARV), 
the latter having caused smallpox, the most serious disease of humankind (102). The 
cross-protection has been utilised in the eradication of smallpox ever since the 18th 
century, when Edward Jenner implemented the vaccination concept and used a less 
pathogenic cross-reactive virus from cows, CPXV, for smallpox protection (163). Over 
the centuries the virus used for smallpox vaccinations has evolved, differing now 
from CPXV (which nowadays very rarely infects cattle) and being called VACV (21). 
Humans were extensively vaccinated with VACV until smallpox was eradicated in 
Europe in 1953 (although minor individual outbreaks occurred) and globally in 1978 
(74, 101). However, the vaccination coverage has consequently diminished, leaving 
the younger generations without protection against any OPVs, of which only CPXV 
is known to naturally exist in Europe (102). Indeed, European CPXV infections seem 
to be emerging (330). In addition to the eminence of CPXV and VACV in smallpox 
eradication and the implementation of vaccination methodology as a whole, VACV 
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has the honour of being the first virus vector carrying foreign functional genes into 
animals (236). Of all OPVs, this thesis concentrates on CPXV, although the term 
OPV is used when discussing cross-reactive antibodies. 
The first descriptions of Borna disease (BD), then known as “hitzige Kopfkrankheit 
der Pferde”, stem from equine practitioners in Germany in the 18th century (328). The 
disease was later named after a huge epidemic in cavalry horses in the city of Borna in 
Saxony at the end of the 19th century (92), and its viral aetiology was established as 
early as 1924 (350). In addition to certain parts of Germany, Austria, Liechtenstein and 
Switzerland have also constituted the classical endemic BD region where sheep, horses 
and rabbits have succumbed to the disease (92). In the 1990s, however, researchers 
started to find BDV elsewhere in the world as a result of mounting interest after the 
first reports of human BDV infections (267). Publications on BDV infection signs in 
multiple species, including the cat, dog and cow, and especially in neuropsychiatric 
human patients, have now accumulated (311). Many of the early PCR findings have 
later been shown or suspected to be caused by contaminations (248, 271), and there 
have been specificity concerns with some of the serological methods (271, 336, 343). 
Nevertheless, carefully verified human BDV infections have also occurred (83), but 
because the transmission between man and vertebrate animals has not been proven, 
BDV is strictly speaking a probable zoonosis. For simplicity, however, it is referred to 
as a zoonosis in this thesis.
Scientific knowledge of CPXV/OPV and BDV has proliferated greatly during this 
thesis work. Recent relevant literature has been included in the thesis, although the 
main hypotheses were formulated based on the situation at the beginning of the 
project. At that time, the first CPXV cases emerged in Finland and human BDV 
infection reports accumulated worldwide. Both pathogens were targeted, because 
they both were possible emerging zoonotic viruses, the presence of which could be 
investigated with similar research material.    
Before this study, the occurrence of CPXV and BDV infections in Finnish fauna and 
humans was unknown. Therefore, the first aims were to establish adequate detection 
methods and screen samples from domestic and wild animals as well as humans 
to determine whether, where and in what species these viruses exist in Finland. In 
searching for and investigating wildlife reservoirs, wild mammal samples from two 
other Eurasian regions, Russian Buryatia in Siberia and northern Germany, were 
included, and an experimental BDV infection of the bank vole conducted. 
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2. liter atur e r ev iew
2.1 Description of the pathogens
2.1.1 Cowpox virus
Cowpox virus (CPXV) belongs to the family Poxviridae, subfamily Chordopoxvirinae 
and genus Orthopoxvirus (OPV) (54). This genus contains several cross-reactive 
and -protective species (Table 1). Other Chordopoxvirus genera, namely Parapox-, 
Leporipox-, Capripox-, Avipox-, Suipox-, Yatapox- and Molluscipoxvirus, include several 
other human- or animal-pathogenic and zoonotic viruses that do not cross-react with 
OPVs (74).
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Camel Nil Africa, Asia
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Raccoons Nil Eastern USA
Taterapox virus, 
TATV
Gerbils Nil western Africa
Vaccinia virus, 
VACV

















CPXV virions, 200 nm x 250–300 nm in size, are brick-shaped particles consisting 
of a surface membrane, a core including an enveloped nucleocapsid, and lateral 
bodies. During the replication cycle, extracellular, often enveloped, and intracellular, 
nonenveloped but mature virions are produced (Fig. 1). Extracellular virions initiate 
the infection, probably using macropinocytosis and apoptotic mimicry like the close 
relative, VACV (210). In the host cell, CPXV may be occluded within eosinophilic, 
type A inclusion bodies. Virions either remain inside the cell, being released as the 
cell lyses, or they bud through the host cell membranes as extracellular enveloped 
virions, consequently adhering to the cell surface and spreading to neighbouring cells 
or externalizing into the environment. (54, 218).
The CPXV genome is a nonsegmented, single linear double-stranded DNA molecule 
of 220 kb (kilo bases). The sequences are redundant terminally (54, 218, 287). The 
middle part of the genome is highly conserved and codes for proteins needed for the 
viral structure and replication. However, genes located nearer to the genome edges 
are slightly more heterogeneous coding for products needed for pathogenicity, such 
as immune modulators, and factors determining the host range and stimulating 
cell proliferation (74, 218, 287). OPV genomes can recombine when infecting the 
same cell (102, 218). Exceptionally for a DNA virus, it replicates in the cytoplasm. 
The replication cycle is complicated, including a strictly regulated cascade of gene 
expression from immediate early to late genes, long DNA concatemers, and a slow and 
complex assembly process (218).
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Figure 1. Replication cycle of orthopoxviruses. A virion containing the DNA genome, 
enzymes and transcription factors attaches to a cell (1) and fuses with the cell membrane, 
releasing a core into the cytoplasm (2). The core synthesizes early mRNA that is translated 
into a variety of proteins, including factors for virulence, DNA replication and intermediate 
transcription (3). Uncoating occurs (4) and the DNA is replicated to form concatemeric 
intermediate molecules (5). Intermediate genes are transcribed and the mRNA translated to 
form late transcription factors (6). The late genes are transcribed, and the mRNA translated 
to form structural proteins, enzymes and early transcription factors (7). Assembly begins with 
the formation of membrane structures (8). The DNA intermediates are resolved into unit 
genomes and packaged in immature virions (IV) (9). Maturation proceeds to the formation 
of intracellular mature virions (MV) (10), which in the case of CPXV are partially occluded 
within inclusions. The MVs are wrapped by Golgi and endosomal cisternae (11) and the 
wrapped virions (WV) transported to the cell periphery (12). Fusion of the WVs with the 
plasma membrane results in the release of extracellular enveloped virions (EV) (12). An 
actin tail polymerizes beneath the EV (13) resulting in virus-induced, motile microvilli, on 
the tip of which most EVs adhere in the search for neighbouring cells.  Reprinted from (218), 
with permission.
19
2.1.2 Borna disease virus
Borna disease virus (BDV) was for a long time the sole member of the family 
Bornaviridae in the order Mononegavirales (81). Recently, however, its relatives, 
avian bornaviruses (ABV) have been detected in psittacine birds with proventricular 
dilatation disease (176). 
BDV is an enveloped, 80–100 nm sized, noncytopathogenic, and strictly cell-associated 
virus causing slowly progressing, chronic infections of neurons in vivo but infecting 
several cell lines in vitro (76, 77, 192). BDV enters the target cell via receptor-mediated 
endocytosis (192) and leaves it by budding through the plasma membrane to the 
adjacent cell (most frequently) or intercellular substance (178, 195) (Fig. 2). The 8.9 kb 
single negative-stranded RNA genome replicates, as an exception among RNA viruses, 
in the nucleus (52, 53, 71, 82). By utilising splicing and alternate, overlapping reading 
frames, BDV uses its small genome effectively (Fig. 3) (53, 192). The genome encodes 
six proteins. The 38/39/40 kDa nucleoprotein (p40, N) is the most abundant of these, 
although when the infection becomes chronic, its molecular ratio to the 23/24 kDa 
polymerase cofactor phosphoprotein (p24, P; (309)), with which it forms complexes, 
decreases (332, 333). N and P are parts of the ribonucleoprotein (RNP) and they have 
an important role in the shuttling of the RNP between the nucleus and cytoplasm, and 
consequently in the control of the replication cycle (177, 192, 310). Phosphorylation of 
the P protein also contributes to efficient viral dissemination (276). In addition to these 
most abundant proteins, the BDV genome encodes protein p10 (X), matrix protein 
p16 (M), glycoprotein p57 (G, gp94 when glycosylated; further cleaved to gp43 and 
gp51), and RNA polymerase (L) (192, 310, 331). Polymerase activity is important in the 
adaptation of BDV to new hosts (5, 6), and X protein inhibits apoptosis, being essential 
for host survival (251). M and G proteins are essential structural proteins needed for 
the formation of BDV particles (242). BDV uniquely limits its genome amplification 
by trimming the genome at the 5́  terminus, which may favour noncytolytic viral 
persistence and the evasion of the antiviral host response (122, 278, 279). BDV infection 
produces an extremely low level of infectious virus particles per cell, although the cells 
express high BDV RNA and protein levels (76, 310).
Figure 2. The spiked Borna disease virus has just budded from a cell and become an extracellular 
particle. Electron micrograph; bar = 100 nm. Reprinted from (178), with permission.
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Figure 3. Genomic organization and transcription map of BDV. N, nucleoprotein p38/
p40N; X, protein X p10; P, phosphoprotein p24; M, matrix protein gp18; G, envelope 
glycoprotein gp94; L, polymerase protein p190; S1–S3, transcription initiation sites; T1–T4 
and t6, polyadenylation/termination sites; SA1–SA3, splice acceptor sites, SD1 and SD2, 
splice donor sites; ESS, exon splicing suppressor. The positions of the sites are given for the 
antigenome in parentheses. Positions of the introns (I, II, III) are also indicated. Reprinted 
from (310), with permission.
Very recently, ancient, endogenized bornavirus-like (EBL) sequences were detected in 
the genomes of humans and several other vertebrates (27, 155). The most commonly 
found EBL resembled the N gene (EBLN), and was the only EBL found in primates 
as well as in the guinea pig, squirrel, lamprey, and a few exotic animal species. In the 
genomes of the lemur, mouse, rat, microbat, wallaby, and a few fish species, however, 
either the L or M gene was detected in addition to or in spite of the N gene (27). Most 
EBLs contain numerous stop codons, thus remaining untranslated, but at least one 
human EBLN has been reported to interact with cellular proteins, indicating a natural 
function (155). The possible biological function of EBLs remains to be elucidated.
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2.2 ecology anD epiDemiology 
2.2.1 Stability of the viruses
OPVs are stable in the environment. Smallpox virus VARV is stable in scabs for 
3–16 weeks, and ECTV in blood spots for up to 11 days (reviewed in (97)). VACV 
maintains its titre in vaccine vials at -20, 0, 4, or 25 °C for at least four days (188), and 
it is stable in numerous organic substances and water (1, 97). Few stability studies have 
been conducted on CPXV, but as it is biochemically equivalent to these other OPVs 
(218) it behaves similarly (199), and can be estimated to remain in the environment 
for days to months. The infectivity of free OPVs is readily destroyed at 56 °C and by 
ultraviolet light, as well as by low concentrations of formalin, lye, chlorine, iodine, 
peracetic acid, and hydrogen peroxide, but notably, cell-bound or dried viral particles 
withstand them for longer (199).
BDV remains stable for at least two years at -70 °C, one year at -20 °C, three but not 
four months at +4 °C, one week at +20 °C, two days at +37 °C, and 15 to 70 min at 
+56 °C (77, 195). It also tolerates alkaline and acidic pHs and drying quite well (77, 
192, 195). BDV is sensitive to common disinfection methods including heat, organic 
solvents, detergents, chlorine, formaldehyde, a pH below 4 and ultraviolet light (77, 
195). 
2.2.2 Geographical distribution
Natural CPXV or closely related OPV infections exist in many Eurasian countries 
(Fig. 4). In most of them, it has been possible to carefully verify the existence of CPXV 
with virological and molecular methods, but in some areas the distribution map is 
based on serology (184) or the molecular methods have not reliably differentiated the 
infecting virus species from other OPVs (61).
Signs of BDV infection, including antibodies, antigen, RNA and/or virus itself, have 
been reported from all continents except for South America (Fig. 4). The highest 
clinical incidence in animals and the verified classical Borna disease cases, however, 
are restricted to central Europe (90, 299). As several PCR amplicons retrieved from 
animals and humans outside the classical endemic central-European area resemble 
those of control strains, many PCR results have been suspected to be caused by 
contaminations (89, 91). Furthermore, some epidemiological studies have been 
conducted based on a triple enzyme-linked immunosorbent assay (ELISA) method, 
which was published without negative controls, but is claimed to detect circulating 
BDV immunocomplexes (CIC), antigen, and antibodies (47). Its results have not 
been reproducible or confirmable with other methods (80, 343). However, these 
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discrepancies cannot explain the detected BDV antigens or antibodies with other, 
reproducible methods, e.g. immunostaining and IFA. Thus, although it seems probable 
that not all BDV reports are reliable, the virus or its close relative is widely distributed. 
whether some of the findings are in fact caused by ABV, EBLs or as yet unknown 
bornaviruses remains to be shown. 
Figure 4. Distribution of natural CPXV or closely related OPV infections (�) (51, 61, 114, 
151, 184, 203, 214, 219, 223, 305, 315, 322, 346) and reported signs of BDV infection 
(�) (13, 14, 42, 65, 110, 124, 148, 158, 196, 201, 212, 221, 257, 267, 269, 285, 338, 
347, 351). Countries such as Italy and the Czech Republic, the BDV findings of which 
are solely based on the controversial triple ELISA method, have been omitted (80, 245, 
256). New locations for OPV and BDV identified in this study are marked with � and �, 
respectively (174, 175, 241).
2.2.3 Species diversity
In contrast to most other poxviruses, which have only one host, CPXV can infect 
numerous vertebrate species. In addition to the cat, which is the most commonly 
detected victim of CPXV, infections have so far been detected in three primate 
(humans, the Barbary macaque, marmoset), eleven other feline (the cheetah, lynx, 
lion, leopard, black panther, ocelot, jaguar, puma, far eastern cat, Bengal cat, 
jaguarundi), six other carnivorous (the dog, fox, arctic fox, bandeed mongoose, stone 
marten, bearcat), four cloven-hooded (the wild boar, okapi, cow, lama), four odd-toed 
ungulate (the horse, black rhinoceros, white rhinoceros, tapir), fourteen rodent (such 
as the beaver, bank vole, yellow-necked mouse, ground squirrel and Patagonian mara), 
and three other animal species (the Asian and African elephant, anteater, common 
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shrew) (reviewed in (98, 219)). Despite the wide host range, only a few species are 
capable of effectively transmitting the virus further. These principal hosts maintain the 
virus in the population, and are considered to include at least the bank vole (Myodes 
glareolus), field vole (Microtus agrestis), and long-tailed field / wood mouse (Apodemus 
sylvaticus) (63, 292). In addition, numerous other rodent species may become infected, 
but their role in viral epidemiology is unclear (96, 98, 202, 204, 317, 318). Hosts 
predominantly not transmitting CPXV further are termed incidental hosts, and even 
the cow belongs to this group. Therefore, “cowpox” is a misnomer and should be 
updated to “rodentpox” according to the principal reservoir hosts. 
BDV has long been known to infect and cause disease in horses (351). Later, natural 
infections with BDV or a BDV-like agent have also been verified in zoo animals (the 
monkey, sloth, llama, alpaca, pygmy hippopotamus; (160) and reviewed in (90, 158)), 
the goat, deer (reviewed in (92)), sheep (212), rabbit (211), cat (33, 164, 196, 229, 
257, but 226), cow (58), human (83), dog (338), lynx (84), and recently, the shrew 
(150). Evidence also exists of infections in the ostrich (200), fox (78), mallard and 
jackdaw (36), macaque (127), and raccoon (126). In addition, this neurotropic virus 
experimentally infects the tree shrew, rhesus monkey, chicken, rat, mouse, hamster, 
Mongolian gerbil, and guinea pig (reviewed in (250)). Despite the wide possible host 
range, the incidence of BD in species other than horses and sheep appears low (90).
As sporadic and relatively poorly-known diseases, both cowpox and Borna disease 
commonly seem to escape diagnosis.
2.2.4 Phylogeny and molecular epidemiology
Most known OPV genes are highly conserved within the genus: particularly those 
located in the central genome commonly exhibit a nucleotide identity higher than 
90% (74, 88, 193). However, if genes that are more variable are analysed, all other 
species isolates in this genus cluster together and separately from other OPV species, 
but CPXV isolates often scatter in several phylogenetical clades or restriction pattern 
groups (Fig. 5) (120, 193, 214). Some isolates and genes resemble more the VACVs 
and others close in the VARV/CMLV group (120, 131, 146, 193). There is evidence of 
recombination, which might partially explain this phenomenon (120). Many scientists 
have even argued that different CPXV isolates should be separated into diverse species 
instead of referring to all of them as CPXV (120, 193). The clustering of CPXV isolates 
shows little correlation temporally, geographically or according to the species of origin 
(172, 193, 213), although evidence of slight geographical clustering in Scandinavia has 
recently emerged (132). 
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Figure 5. Phylogenetic tree of 12 OPVs obtained by the maximum-likelihood method using 
amino acid sequences of 12 OPV proteins (VV-COP C6L, C7L, N1L, K2L, F2L, F4L, 
F6L, F8L, A56R, B1R, B5R, B15R) encoded in the terminal regions of the genomes. The 
maximum-likelihood tree is shown in an unrooted format. The bootstrap values from 1000 
replica samplings and the divergence scale (substitutions per site) are indicated. Reprinted 
from (120), with purchased permission. 
The genomic sequence of BDV ― then representing all known bornaviruses ― was 
long thought to be extremely conserved, as the nucleotide sequences from isolates or 
PCR amplicons were more than 95% identical (39, 90, 149, 277, 299). As BDV has 
an RNA genome and lacks the proof-reading activity of its polymerase, it has also 
proven surprisingly stable in persistently infected cell cultures (107). A strict selection 
pressure, probably related to a complicated transmission chain including several 
species, such as with alpha- and rabies viruses (152, 334), has been assumed to provide 
constraints to genomic variation (90). More recently, however, one strain from an 
Austrian region where BD had not previously been diagnosed, has been detected with 
only 85% identity to the previous variants (228). This finding indicates that additional 
BDV variants with distinct features may be present, but probably escape detection 
by the common PCR methods. Even the most similar central European BDV strains 
present with minor differences according to their geographic, but not host species, 
origin (179). Recently, a BDV-related new virus species, ABV, was found with modern, 
virus family-specific hybridization methods. ABV isolates possess a nucleotide identity 
of only 60% to the known BDV strains (Fig. 6) (176). Surprisingly, the very recently 
observed, 40-million-year-old bornavirus-like genes in vertebrate genomes have also 
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retained their similarity to current BDV strains well: the EBL sequences are 40% 
identical to the current viruses at the amino acid level (155). Thus, bornaviruses overall 
seem not to evolve according to a molecular clock similarly to other RNA viruses, but 
are highly conserved (155). 
Figure 6. Phylogenetic tree of currently known bornaviruses based on 5.5 kb-long nucleotide 
sequences and the neighbour-joining method. Adapted from (153), with permission. BDV, 
Borna disease virus; ABV, avian bornavirus
2.2.5 Other epidemiological facts
Although CPXV and BDV both infect numerous animal species, they are not very 
contagious within a domestic animal species, and apparently not from domestic 
animals to humans. Human CPXV infections most commonly arise from cats or rats 
(23, 162), but direct transmission from the cheetah, cow and Asian elephant has also 
occurred (reviewed in (98)). The infection source, however, often remains unresolved 
(23). Despite being the most common infection route, CPXV is not easily transmitted 
from cats to humans (31). The risk of human infection is probably higher if the cat’s 
condition is not diagnosed and proper protective measures undertaken. Human-to-
human CPXV transmission has not been proven (23), and symptomatic cat-to-cat 
transmission of natural cowpox is also rare (31). This has been verified in experimentally 
infected cats: the sentinel contact cats seroconvert but remain asymptomatic (32). 
Similarly to cowpox in cats, cases of Borna disease in horses and sheep are also mainly 
sporadic, and transmission within or between the domestic species such as sheep, 
horses, and cattle rarely if ever occurs (reviewed by (299)). However, the stable mates 
of BD animals frequently have or gain antibodies, indicating a common transmission 
source (299, 321). Although the disease seems to appear in cats of the same regions in 
the course of time (339), contact with cats in the household or fighting with other cats 
are not risk factors for feline Borna disease (33). On the contrary, roaming free in a 








majority (22 of 25, 80%) of the cats with verified cowpox were found to originate from 
rural or suburban environments, and at least 76% of them evidently hunted rodents 
(31). This type of epidemiology naturally stems from the fact that the principal hosts 
for CPXV are wild rodents, in which CPXV mainly circulates, and only occasionally 
infects the incidental hosts such as cats and humans (63). As described above, 
the same is indicated to apply to BDV, as also further evidenced by several other 
epidemiological data sets suggesting a reservoir in small wild mammals (90, 299). 
First of all, BDV prevalence is higher on farms lacking proper rodent control and 
hygiene. Secondly, focal BDV epidemics are observed independently of the region and 
species at 2- to 5-year intervals (90, 92), which could be related to fluctuation in wild 
rodent numbers. Thirdly, BDV is transmitted horizontally in laboratory rats via urine 
(273) and probably vertically (reviewed by (90)), and fourthly, BDV strains cluster 
geographically rather than according to the species or year of isolation, suggesting that 
transmission within a domestic species is uncommon (179).  
There is, however, one major difference in the epidemiology of BD and cowpox: the 
incidence of BD in horses and sheep peaks in March to June and in cats between 
December and March, although cases in all these species occur year-round (90, 92, 
196). Quite the contrary, the striking peak in feline and human cowpox number 
appears in late summer and autumn (July to October), thus better reflecting the rodent 
numbers, which peak in the same season (172, 244, 325). The temporal appearance 
of cases is strictly associated with the incubation period. For CPXV it is short, from 
3 days to 3 weeks, so the cases are seen almost simultaneously with the peaks in 
rodent numbers. The natural incubation period for BDV is much longer: based on 
practical experience it is 2 to 3 months (90, 160), but probably even up to 143 days 
in horses (207) (see also “2.3.2 BDV infections”). If this holds true, horses and sheep 
should become infected between November and April, at the time when the few living 
rodents seek shelter inside or start mating.  
Despite the above-mentioned numerous epidemiological facts and the recent finding 
of BDV infection in shrews (150, 252), some scientists object to the “BDV reservoir 
theory”. They support their argument with the extremely high BDV prevalence 
(30-100% (238)) in humans and horses so enabling direct transmission between 
individuals. These prevalences are, nevertheless, based on the controversially discussed 
triple ELISA method ((41, 47, 343); see “ 2.2.2 Geographical distribution”), and 
other research groups utilising other methods have suggested much lower prevalences 
(summarized by (158)).
Both cowpox and Borna disease are sporadic maladies. Altogether, around 100 reported 
human and tens of animal cowpox cases have occurred. Moreover, the incidence of 
Borna disease even in the best known hosts, horse and sheep in the classical endemic 
region, has declined from the large outbreaks affecting thousands of patients in the 
19th century to fewer than 100 cases in each species a year (reviewed in (299)).
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2.3 Diseases causeD By cow pox anD Borna Disease 
v iruses
2.3.1 Natural CPXV infections
Clinical cowpox is most commonly diagnosed in humans and cats, although several 
other species may succumb to the disease (Fig. 7, Tables 2 and 3). CPXV is considered 
to enter an animal host through the skin, mucosal membranes or respiratory tract. 
After initial infection, the virus moves to regional lymph nodes and spreads again 
from there, resulting in primary viraemia and multiplication in reticuloendothelial 
cells. After the multiplication and paralleling the incubation period of usually 7–14 
(3–21) days, secondary viraemia combined with rash, constitutional symptoms and 
virus excretion ensues (32, 74). In humans, skin abrasions are the most common 
portal of entry, typically resulting in lesions either on the fingers, hands or face (23). 
The normal clinical course of infection in immune competent individuals of most 
species, and also in humans, includes inflamed and painful macular, papular, vesicular, 
pustular, ulcerative and eschar stages of 0.5–2 cm of size followed by healing in 3–12 
weeks (23, 31, 56). Constitutional symptoms are very common in humans but less 
commonly observed in cats (23, 31, 117). On the contrary, secondary lesions are much 
more common in feline than human patients, although they both usually present 
with few (one to two) primary lesions (23, 31). Localized skin lesions show necrotizing 
dermatitis and folliculitis characterized by hypertrophy and basal cell proliferation 
together with inflammatory infiltration; A-type inclusion bodies are pathognomonic, 
although rarely observed in human lesions (23, 74, 172).
Figure 7. Healing cowpox lesions on a cat’s head. Photo:  Malcolm Bennett, with permission.
28
OPVs, especially CPXV with its large genome, encode and express a large number 
of intracellular and secreted proteins that modify the host responses to the OPV 
infection (74). These immunomodulatory proteins, for example, inhibit apoptosis and 
immune functions of dendritic cells, and bind to host cytokines, components of the 
complement system, chemokines, interferons, and their receptors (74, 133). 
In some individuals, especially those who are immunocompromised or 
immunomodified, cowpox can be severe or even lethal (31, 72, 117, 151). For example, 
in human atopic dermatitis, the unusual abundance of Th2 cytokines downregulates 
the antiviral innate immunity of keratinocytes, allowing increased replication of 
OPVs (74). Examples of different clinical pictures are presented in Tables 2 and 
3. Differential diagnoses in cats include other severe ulcerating and necrotizing 
dermatitis, e.g. eosinophilic granuloma, neoplasia, pyoderma, mycosis, pemphigus, 
and herpes- or calicivirus infection (172, 244). In humans, cowpox may resemble 
infections with herpesviruses (especially varicella-zoster) or parapoxviruses from 
ruminants, i.e. farmyard poxes, or anthrax, cat scratch disease, i.e. bartonellosis, 
































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































BDV experimentally infects animals via various routes: intranasally, intracerebrally, 
intramuscularly, subcutaneously, intradermally, and less efficiently intravenously, 
but not intragastrically (60). Natural transmission routes are unproven. Nonetheless, 
successful experimental intranasal infection of rats (60, 216, 301), mice, sheep, and 
horses (299) and the presence of BDV antigen or -RNA in the olfactory epithelium, 
nerves and bulb of naturally infected horses strongly point towards a nasal or olfactory 
route, although trigeminal and pharyngeal nerve routes cannot be excluded ((38) 
reviewed in (262, 301)). Infection most probably occurs via excreta: experimentally 
chronically infected rats excrete BDV, for instance, in tears, saliva and urine, and can 
infect other rats in close contact (216, 273, 303). In a few naturally infected horses and 
sheep, BDV RNA is found in salival, nasal and conjunctival fluids, but surprisingly, 
infectious virus is nonexistent in asymptomatic animals (148, 186, 260, 321) and 
rarely exists in symptomatic horses (148), further indicating possible transmission 
from a reservoir (186, 260, 321). In addition to horizontal transmission, BDV has 
transmitted vertically in experimentally infected mice (231), probably rats (reviewed 
by (90)), and possibly from a pregnant mare to her fetus (125).
BDV spreads intra-axonally from the inoculation site into the central nervous system 
(CNS) (60). when in the rat CNS, the virus rapidly spreads and can be demonstrated 
in all cortical and brain stem areas at day 10 p.i. (301). Naturally infected horse brains 
are also widely BDV positive (38), which may be followed by intra-axonal centrifugal 
spread to peripheral nerves, and occasionally, to other than neuronal cell types (158, 
181, 186). 
In cats experimentally infected by intracerebral (i.c.) inoculation, the first symptoms 
may arise on day 14 p.i., but it may take 75 days to detect them or a cat may remain 
asymptomatic for at least 6 months (164). Ponies experimentally infected by i.c. 
inoculation had an incubation time of 15–26 days (171), and older studies have 
proposed incubation periods of 24–143 days in horses, 32–85 days in sheep, 18 days 
to months in rabbits, 20–390 days in guinea pigs, 20–90 days in adult rats, and 36 
days in hens (207). However, experienced clinicians estimate an average incubation 
time of 2–3 months in horses (90), and recent data indicate a minimum of 2 months 
in alpaca (160). Persistent subclinical infections, resulting either from a very long 
incubation period or the low-pathogenic character of the BDV infection or both, are 
common. Indeed, during a follow-up of 1–2 years in naturally infected animals, only 
a proportion of the antibody-positive individuals (20% of horses, up to 40% of sheep) 
developed symptoms ((148, 321) and the review by (299)). In naturally infected, 
diseased animals, BDV infection manifests as a peracute, acute or subacute disease 
with nonpurulent meningoencephalitis, although milder manifestations are also seen 
(Table 4; (34)). Different combinations of simultaneous or successive neurobehavioural 
alterations are noticed (38, 119, 158, 212, 259). Paralysis is common, and in the 
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classical BD form, death occurs in 60–80% of the animals by 5 weeks after the onset 
of symptoms. Spontaneous recovery is possible, but is often accompanied by altered 
behaviour for the rest of the animal’s life, and occasionally leads to the recurrence of 
severe encephalitis (119, 158, 261). 
In experimental murine infections, the disease onset correlates with viral expression in 
the lower brain stem and cerebellum, although BDV is mainly found in the cerebral 
cortex and hippocampus (332). In infected rats, BDV has several pharmacological 
effects in the brain, such as upregulation or activation of certain kinase pathways, 
transcription factors and genes resulting in either dopaminergic, and finally fatal 
meningoencephalitic disease in immunocompetent adults, or persistent, global 
development disorder manifesting with hyperactivity and learning disturbances in 
those who are neonatally infected (250, 294, 295). Rat infection with one particular 
strain leads to the development of obesity syndrome, which has been hypothesised to 
result from neuroendocrine dysregulation by BDV (145).   Furthermore, BDV seems 
to impair the functions of nerve cells through interference with the protein kinase 
C-dependent signalling by the P protein, by blocking stimulus-induced synaptic 
activity, one form of neuronal plasticity thought to be important for learning and 
memory (324). Moreover, BDV effectively inhibits activation of the intracellular 
pathogen recognition receptor RIG-I, which leads to protection from the antiviral 
actions of innate immunity (122). Recent studies have revealed additional mechanisms 
by which BDV interacts with host cells and affects innate immunity (254).
Interestingly, BDV pathology is partially related to the T cell-mediated immune 
response (128, 301). CD4+ (helper) T cells are the most abundant and predominate 
in the perivascular inflammatory cuffs, whereas cytotoxic CD8+ T cells are present 
in the brain parenchyma, especially in the vicinity of possible degenerating neurons, 
indicating a role in the pathogenesis of BD (301). Indeed, athymic, splenectomised 
or otherwise immunocompromised rhesus monkeys, mice or rats do not show BD or 
acute inflammatory reaction, while the untreated animals succumb to severe, even 
lethal BD ((128, 222, 302) reviewed in (301)). This has been attributed to the presence 
or absence of the CD8+ T cells and a delayed type hypersensitivity reaction, although 
sole production of certain proinflammatory cytokines, such as γ-interferon, may also 
contribute, as recently shown in feline infections (301, 340).
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Table 4. Manifestations of Borna disease in natural host animal species. 
Species Clinical manifestation Pathological 
manifestation
References
Horse Begins with excitability or depression; 
continues with swallowing 
difficulties, ataxia, imbalance, 
decreased sensory, proprioceptive 
and reflex functions; ends with 
severe excitability, aggressiveness, 
or lethargy, and circling, paresis, 




(38, 92, 119, 
158, 259, 306)
Ataxia, narcolepsy, behavioural 
changes, apathy, colic, abnormal 
movements
Not analysed (34, 44)
Sheep Altered behaviour, progressing ataxia, 






Cow Anorexia, anxiety, ataxia, paresis, 
circling, paralysis
Encephalitis (58, 230)
Alpaca Lack of sexual desire, convulsions, 
prostration, death
Meningoencephalitis (160)





Dog Salivation, mydriasis, circling, coma Meningoencephalitis (232, 338)
Cat Mental and behavioural changes, 





Ostrich Incoordination, paresis No specific lesions (200, 201)
2.3.3 Human Borna disease?
As BDV infects a wide variety of animal species with a predilection for the limbic 
system, and occasionally induces persistent emotional, cognitive and behavioural 
alterations in experimental animals, including primates and their ancestors (297, 302), 
the question has arisen of whether the virus could also be a human pathogen and 
cause neuropsychiatric disorders. The first evidence of human infections was, indeed, 
reported in 1985: 0.43–12.5% of patients with diverse psychiatric disorders had BDV-
antibodies in the serum whereas the prevalence in the control group was <0.5% (11, 
267). The seropositive patients were diagnosed to have a primary major depressive 
disorder. The majority of the later studies have also revealed higher BDV marker 
prevalence in some patient groups than in controls, i.e. in unspecified psychiatric in-
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patients, neurotic, personality adjustment and mood disorder patients, schizophrenics 
and patients with chronic fatigue syndrome (summarized by (59, 62, 246, 308)). 
However, signs of infection are not present in all patient groups, and control or 
comparison groups also sometimes harbour signs of BDV infection. Furthermore, 
despite the association of detected BDV markers with some psychiatric diseases in 
numerous studies, conclusions on the causal relationships are impossible to draw. The 
situation is even more complicated by the facts that no consensus exists on the method 
which should be used for BDV diagnosis (41, 62, 271, 336, 343), and that based 
on the sequence identity, many PCR results and even virus isolation from human 
peripheral blood cells have been suspected to have arisen from contamination by a 
control strain (89, 91, 190, 227, 248, 271, 284).
Despite the controversies, there are researchers who consider that the existence of 
human Borna disease has been demonstrated and it is common (45-48, 194, 238, 
239, 280). Especially controversial, however, are findings based on the ELISA method 
detecting BDV antibodies, antigen and CICs ((47, 343); see “2.2.2 Geographical 
distribution”). Moreover, the lack of specificity of other serological methods has been 
surprisingly strongly suspected if compared to the diagnostic methods for other viral 
infections (271, 336). Nonetheless, a few human BDV infections have been carefully 
verified with a combination of methods including reproducible and controlled antigen 
detection by immunohistology, as well as RNA detection by in situ hybridization and 
RT PCR in the brain tissue of patients suffering from hippocampal sclerosis (83). 
Furthermore, the recent EBLN findings in primate genomes prove that our ancestors 
were infected with a bornavirus (27, 155). These facts convincingly verify that BDV 
can indeed infect humans. However, the frequency of human infections, the role 
of EBLNs in human disease, and the existence of human Borna disease are still 
questionable (27, 90, 159, 191, 298, 299). 
2.4 infection Kinetics anD Diagnosis of cpx v anD 
BDv infections 
2.4.1 Immunity and detection of serological response 
In acute OPV infection, cytokines and cytotoxic CD8+ T cells are crucial to control the 
disease, but for complete virus clearance and recovery, B cell functions and therefore 
antibodies are necessary (64). In the mouse model, antibodies also prevent virus 
from forming pock lesions on the skin and inhibit transmission (64). Neutralizing 
antibodies are assumed to prevent a reinfection in humans, and as cross-reactive 
antibodies after infection with one OPV persist even for decades, the relevance of 
smallpox vaccination in inhibiting all OPV infections in humans is easily deduced (74, 
173). After experimental feline infection, haemagglutination-inhibiting antibodies are 
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present on days 6–16 p.i. and thereafter, corresponding to approximately one week 
after the onset of skin lesions, but a high titre of neutralizing antibodies seems to need 
a few more days to develop (29, 32, 111). Antibodies last no less than 6–10 months 
in cats (29, 111). Rodents experimentally infected intradermally and subcutaneously 
become seropositive 9–12 days p.i., but the majority of those infected with a low dose 
or via the oronasal route remain antibody-negative (30). 
In contrast to acute OPV infections, antibodies do not seem to play a protective role in 
persistent BDV infections: even 60–70% of naturally infected animals do not mount 
an antibody response at all, and if they do, the titre is low and neutralizing antibodies 
are detected late, if ever (119, 135, 164, 271, 321). Furthermore, seroreversion may 
be possible (142). Although the relevance of neutralizing antibodies is difficult to 
determine in natural infections, prophylactically administered neutralizing antibodies 
against the major glycoprotein prevent infection and encephalitis in experimentally 
infected rats (109). If neutralizing antibodies are administered simultaneously with 
the virus, they can still inhibit the viral spread to peripheral tissues and prevent virus 
excretion and transmission, although not the persistent BDV infection itself (303). 
Immunosuppressed rats (which present with subclinical BD) are competent to mount 
a humoral but not a cellular immune response (303). 
Horses and cats experimentally BDV-infected through i.c. inoculation seroconvert 
one month p.i. (164, 171). Depending on the viral strain, cats have a humoral response 
to the P protein or both N and P proteins (164). This difference may be related to the 
stage of viral persistence: the N:P ratio decreases as the infection becomes chronic 
(186, 333). Overall, the serological response is stronger in experimentally than in 
naturally infected animals although not constantly detected in either animal group 
(147, 164, 216, 268).  
BDV antigen has been claimed to be present in the peripheral blood and to commonly 
bind to BDV-specific antibodies, so forming circulatory immunocomplexes, CICs (47). 
CICs have been detected with a reverse-type sandwich ELISA by several, associated 
research groups reporting high BDV prevalences among humans, horses and cats (41), 
although other researchers have been unable to reproduce them (343). Lower prevalences 
are found with more conventional methods, of which the immunofluorescence assay 
(IFA) is the most commonly used (267, 271). Immunoblotting, immune precipitation, 
the electrochemiluminescence immunoassay as well as different versions of the ELISA 
method are also used for BDV antibody detection from serum and cerebrospinal fluid 
(reviewed in (271)).
Measurement of the avidity, i.e. functional affinity, of antibodies has long been used 
in the timing of primary infections: a high proportion of strongly-bound, urea-
resistant antibodies indicates long-term (weeks to years old) adaptive immunity, 
whereas in acute infection the proportion is low (140). within the debated field of 
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human BDV infections, high avidity, or especially the lack of it, has also been utilised 
as an indicator of the specificity of the antibody response (8, 37). Although most 
BDV antibody findings in humans have been of low avidity (8), high-avid serological 
responses also exist (37). 
As CPXV infections in incidental hosts cause clearly detectable dermal lesions, which 
are easily sampled and studied, the detection of antibodies plays a smaller role than 
in BDV diagnosis. However, and especially in the asymptomatic reservoir hosts, 
OPV antibodies have been detected with the haemagglutination inhibition test, 
neutralization assay, IFA, and competitive ELISA (69, 111, 202, 317). 
2.4.2 Viral kinetics and its detection
CPXV tends to cause a localized infection in humans, although viraemia can 
occasionally be detected (224). The lesions contain large titres of virus, especially in 
the vesicular stage, so the best material for the detection of CPXV ― by electron 
microscope, virus isolation, immunostaining, and PCR ― is a biopsy or swab of a 
lesion. The same applies to animals, although feline infections in particular are 
more commonly generalised than those of humans. Patients are often presented at a 
late, eschar stage of the disease, when the virus titre may be low but still detectable 
with PCR. Histopathological lesions, especially eosinophilic A-type inclusions, are 
characteristic in the early course of the disease and may be sufficient for a cowpox 
diagnosis in cats, but specific methods for orthopoxviruses are needed for a verified 
diagnosis at least in humans, who seldom present with the pathognomonic inclusions 
(172, 244, 325). 
Reliable diagnosis of BD is impossible intra vitam (271). RT nested PCR methods have 
amplified the viral genome from peripheral blood, but the results are of low diagnostic 
value, as numerous asymptomatic animals and humans are also reported to harbour 
BDV RNA in blood (reviewed in (158)), and BDV viraemia overall is controversial 
(299). RNA in blood might, however, be indicative of Borna disease if pursued very 
carefully, avoiding contamination, and when combined with the clinical picture and 
antibody detection. In addition, the detection of BDV antigen in the peripheral blood 
has been reported, but has been controversially discussed (see “2.4.1 Immunity and 
detection of serological response”). The definitive BD diagnosis is possible only post 
mortem by demonstrating the virus or viral markers in the brain (271). Virus isolation 
is the most reliable confirmatory method, although very slow and complicated by 
neurotropism of the virus and by an often very low virus titre (76, 118, 186). The 
diagnosis can be made several weeks earlier if based on the detection of viral antigen 
with immunohistology, and/or viral RNA with in situ hybridization or RT PCR 
(186, 271). As usual with such noncytopathogenic, cell-associated, persistent virus 
infections (9), the results from different methods are not always congruent, reflecting 
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the low viral amount (186). BDV is most often present in the olfactory bulb, caudate 
nuclei, hippocampus, lateroventral cerebral cortex, and medulla oblongata (186), so 
these represent the most important sampling sites for BDV detection.
2.5 treatment anD prevention of cow pox anD 
Borna Disease
Supportive and symptomatic treatments so far remain the only authorized treatment 
for both cowpox and Borna disease. For cowpox, sterile bandages and antimicrobial 
drugs may be necessary to control secondary bacterial infections, and minor surgical 
interventions have occasionally been performed in the late phase of the infection 
(23, 313); corticosteroids are contraindicated (18, 23, 243, 335). Anti-VACV 
gammaglobulin has been used for severe human cases (23, 93, 329).
CPXV among other OPV infections have been prevented or attenuated by smallpox 
vaccinations in humans in the past (101). As always, the protection is not full, at least 
not in all individuals, as CPXV infections have occurred despite recent vaccination 
(23). In fact, CPXV may evade the existing immunity by its direct deposition in 
skin (23). However, reports of CPXV infections have markedly risen following the 
cessation of smallpox vaccinations (330). whether this is the result of a rise in the 
true incidence or due to increased attention remains to be determined. with another 
OPV infection, monkeypox, a 20-fold increase in incidence during 20 years has 
recently been demonstrated (263). Fortunately, CPXV seems to be of low infectivity 
to humans (23).
In addition to humans, a VACV vaccine has been authorized and used to protect 
exotic animals from cowpox in Germany (reviewed in (182)), and experimental feline 
vaccinations have been pursued (208).
Cidofovir, a nucleoside analog, is effective against CPXV and several other DNA 
viruses (12). As its use is complicated by rigorous side effects, other effective antivirals 
have been rationally searched for, driven largely by the threat of smallpox virus use as a 
biological weapon (7). The most promising candidate antiviral is the compound ST246, 
which interrupts the maturation of OPV particles into enveloped viruses. ST246 is 
effective against VARV, MPXV, ECTV and CMLV, in addition to CPXV (293). It 
has inhibited lethal challenge in rodent experiments (255), and has been successfully 
used in conjunction with cidofovir and intravenous vaccinia immunoglobulin for the 
treatment of a severe human case of eczema vaccinatum (329). Another promising 
antiviral is CMX001, a less toxic derivative of cidofovir (258).
As severe losses were suffered and even more were threatened, vaccination against 
BDV was applied. when inactivated vaccines were shown to be ineffective, virulent 
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virus was applied subcutaneously (92, 194).  Rigorous vaccination was compulsory in 
the former German Democratic Republic in 1962–1992, but the campaign proved 
ineffective. Nowadays, infections caused by these unsuccessful vaccinations possibly 
contribute to the fact that the incidence of clinical Borna disease is still highest 
in horses in Germany (90, 194); the same is slightly indicated by BDV molecular 
epidemiology (179). No vaccination against this persistent infection has since been 
recommended (90, 194), although new recombinant vaccine candidates expressing 
BDV-N mediate protection from the disease, but not from infection in rats (136).
Amantadine sulphate is an antiviral affecting influenza viruses and also showing some 
CNS effect for example in Parkinson’s disease. Its use in the treatment of Borna disease 
has been debated (43, 46, 70, 85-87, 129). As amantadine sulphate is rather safe and 
readily available, it is used at the dose of 2–4 mg/kg for a minimum of 12 weeks in the 
treatment of veterinary patients showing aggravating symptoms. This is despite the lack 
of controlled and blinded studies on its effects (85, 165). Intracerebrally administered 
ribavirin interferes in BDV replication and results in clinical improvement, although 
not in viral clearance in rodent, but its use is compromised by side effects (166, 187, 
215, 296). Some other antivirals have also been developed and tested against BDV, but 
they have so far remained in the initial phase (15, 16, 247, 254, 323).
Because of the lack of effective antivirals and vaccines, the prevention of contact with 
possible virus sources remains the only way to affect the incidence of BDV. Exact 
guidelines cannot be provided, as transmission routes and reservoirs remain to be 
defined, but as the transmission mode seems to be at least oronasal, care should be 
taken to avoid getting secretions or excretions from possibly diseased or reservoir 
animals onto mucous membranes. In addition, improvements in general hygiene in 
animal premises and the separation of horses and sheep have provided some protection, 
but have not led to the elimination of BDV (194).
As for cowpox, although it is not very contagious, lesions contain high amounts of 
virus and should therefore be covered, or their handling with bare, especially abraded 
hands avoided. A simple piece of advice, which most probably protects against both 
CPXV and BDV infections, would be to wash the hands with soap after a contact 
with rodents or any animal secretions, excreta or lesions, before touching the nose, 
eyes or mouth. If this is difficult, gloves or a respirator may help to minimize the 
mucosal contact, and consequently viral transmission. 
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3. aims of the stuDy
CPXV and BDV were previously known or suspected to infect humans and several 
other species in Europe, but their existence in Finland was unknown and diagnostic 
methods absent. Furthermore, wild rodents had been known to act as CPXV 
reservoirs, but the frequency, species diversity and geographic distribution of the 
infection were insufficiently known. As for BDV, wild rodents had been suspected to 
function as a reservoir, but this hypothesis had been insufficiently tested. It had also 
been commonly hypothesised that OPV antibodies and their prevalence resulting from 
smallpox vaccination would be waning in humans as a consequence of the cessation of 
smallpox vaccination, and this could affect the severity of the disease course. This had 
not, however, been demonstrated. The general aim of this thesis was, using various 
approaches, to address these issues, i.e. the importance of CPXV and BDV in Finland 
and in possible host species. The specific aims were to: 
•	 Establish relevant methods for the detection of CPXV and other OPVs as well 
as BDV in Finland (I-IV);
•	 Determine whether CPXV and BDV exist in Finland, and if so, in which 
species (I and II);
•	 Discover how common OPV immunity is in different age groups in Finland (I);
•	 Characterize possible disease cases and clarify their epidemiological context (I);
•	 Establish the hosts and possible reservoir species of these viruses and their 
geographical distribution in wild rodents (I-IV);
•	 Elucidate the kinetics of BDV infection in the bank vole (IV).
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4. m aterials anD methoDs
Most materials and methods are described in the original publications I–IV, either on 
print or as a supplementary material available via the Internet. In the latter case, the 
link is provided in the printed publication and the material printed as an appendix. 
Some methods not explained in detail in the original articles are described here more 
thoroughly. Also, some additional methods are described.
4.1 sampling anD sample stor age 
4.1.1 Ethical permission
National regulations were followed in the trapping of small mammals (I–III). The 
Ethics Committee of the University of Helsinki approved the use of human and 
animal samples and virus isolation protocols in studies I, II and III, and the County 
Administrative Board of Southern Finland approved the facilities and the protocol 
for study IV. Veterinarians signed informed consent forms for the use of their blood 
samples in studies I and III.
4.1.2 Human samples
A total of 499 human serum samples were either received from the diagnostic 
laboratory of Helsinki University Hospital, involving patients suspected to have 
Puumala hantavirus infections (III), or specifically collected at the Annual Veterinary 
Congress (Eläinlääkäripäivät) 2001 (I, III). In addition, two whole blood samples 
were investigated (III). Furthermore, a biopsy sample from a skin lesion together 
with several serum samples were obtained from a hospitalised patient (I), and a DNA 
sample, previously extracted from a pock lesion on a young girl in 1989, was provided 
by the National Institute for Health and welfare (I).
4.1.3 Samples from domestic animals
For Borna research, serum samples from neurologically or behaviourally symptomatic 
horses (n = 108), cats (n = 30), dogs (n = 89) and sheep (n = 2) from different parts of 
Finland were received from veterinarians (III). In addition, samples from asymptomatic 
horses (n = 500), cats (n = 293), dogs (n = 6), cattle (n = 52), sheep (n = 20) and a rabbit 
(n = 1) were collected for BDV and/or OPV screening, either as control material or as 
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specific targets near a patient case (I, III). Fresh tissue samples were available from 4 of 
these horses and from 1 cowpox-suspected cat, and cerebrospinal fluid (CSF) from 11 
dogs; moreover, whole blood was analysed for BDV RNA from 48 horses, 59 cats and 
27 dogs (III, unpublished). A parallel study investigated paraffin-embedded, archival 
brain samples of horses and cats for BDV antigens (141).
4.1.4 Samples from wild mammals and birds
Small wild mammals were collected by snap-trapping (I-III) or live-trapping followed 
by blood sampling and release (III), euthanasia by cervical dislocation (III), or 
housing them in a laboratory, where they gave birth to the animals in the infection 
experiment (IV). Small mammal samples consisted of sera and whole blood samples 
collected from retro-orbital sinus with capillary tubes (I, III, IV), and of blood samples 
collected from the pulmonary cavity post mortem in PBS (I-III; (250b, 289b, 319b)). 
The trapped small mammals were predominantly rodents, which in Finland mainly 
consisted of bank voles (I, IV), but also included many other rodent species (II, III) 
and some common shrews (Sorex araneus) (III). The carcasses were set on dry ice and 
stored at either at -20 °C or -80 °C until aseptically autopsied and sampled (I–III). The 
laboratory bank voles were necropsied and sampled immediately after euthanasia (IV). 
In total, 1600 Finnish, 437 Buryatian (from Baikal region, Siberia, Russian Republic 
of Buryatia) and 270 German wild small mammals were trapped and used for BDV or 
OPV studies, or both (I–III, and Kinnunen et al. unpublished). 
Blood samples from 292 grouse birds (Tetraonidae spp.) were gathered by hunters by 
drying blood in filter paper and later dissolving it in Dulbecco’s PBS (III; (181b)). 
wild predator samples consisted of blood samples from 3 wolves (Canis lupus) and 
145 lynxes (Lynx lynx; III), collected from legally hunted animals by the Finnish 
Game and Fisheries Research Institute and stored at -20 °C. In addition to BDV 
IgG screening (III), these predator samples were also tested for the presence of OPV 
antibodies (Kinnunen et al. unpublished). 
4.2 control material
As BDV-positive control sera, the following material was used: polyclonal rabbit anti-N 
and -P rabbit sera (164), the monoclonal anti-N “Bo18” serum (121) (kindly provided 
by Prof. Peter Stäheli, Freiburg, Germany), as well as sera from experimentally and 
naturally infected cats (164), an experimentally infected rat, and horses with natural, 
verified Borna disease (kindly provided by Dr. Sibylle Herzog, Giessen, Germany). Sera 
from uninfected rabbits, cats and horses were utilised as negative controls. Plasmids 
containing BDV-N and -P sequences for use in the production of recombinant 
antigens were gifts from Prof. Mikael Berg, Uppsala, Sweden (35). (III, IV)
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Control material for BDV RNA and antigen detection included BDV/He80-infected 
and non-infected C6 cells (kindly provided by Prof. Mikael Berg, Uppsala, Sweden), 
BDV-infected and non-infected cat brain tissue (196), as well as paraffin blocks from 
verified Borna diseased horses and experimentally infected mice and rats (gifts from 
Dr Jürgen Hausmann, Freiburg, Germany, and Prof. Christiane Herden, Hannover, 
Germany). Pernilla Syrjä (Helsinki, Finland) and the Animal Experiment Department 
of the University Animal Hospital kindly provided the brain samples from uninfected 
horses, cats and rats.
For the establishment and checking of CPXV methods, serum from smallpox-
vaccinated and non-vaccinated colleagues, CPXV-infected and uninfected rodents 
(kind gifts from Dr Malcolm Bennett and Dr Kim Blasdell, Liverpool, UK, and Dr 
Donata Kalthoff, Insel Riems, Germany) and of VACV-infected calf (kindly provided 
by Dr Irja Davidkin, Helsinki, Finland) were used, in addition to several VACV 
strains (also from Dr Davidkin; I, II) and a plasmid expressing the partial VACV 
HA gene as DNA controls (253) (II). After isolation of the first Finnish CPXV strain 
(I), it was used as the basis for serological studies (I, II). Tissue samples from specific 
pathogen-free laboratory mice were included as negative controls, as well as HEX-
labelled enhanced green fluorescent protein gene added to the samples as an inhibition 
control ((151b); II).
4.3 v irus isolation
All the virus isolation attempts were performed in biosafety level 3 laboratories of the 
University of Helsinki Meilahti campus following strict safety precautions.
4.3.1 Cell cultures
Orthopoxvirus was isolated from tissue samples using the following protocol: A biopsy 
sample from a human patient’s pock lesion, or the lung or liver or both from PCR-
positive rodents were homogenised with a mortar and pestle, suspended 1:10 or 1:20 
in the cell culture medium, i.e. modified Eagle’s Medium (MEM) supplemented with 
2% foetal calf serum (FCS), 0.3 mg/ml glutamine, 0.1 mg/ml streptomycin, 100 IU/
ml penicillin, and 0.25 μg/ml amphotericin B, and pipetted onto almost confluent 
Vero E6 cells without other media. The suspension was incubated for 1 h at 37 °C in 
an atmosphere containing 5% CO2, after which the rest of the medium was added on 
two occasions, one day apart. The cells were further incubated in similar conditions 
and checked daily for cytopathic effects, the culture medium was changed once a 
week and the cells split 1:5 once per two weeks. Through splitting, samples of cells 
and inoculum were also stored at -70 °C for possible PCR, EM and further cultivation 
studies, and cells were spotted on IFA glass wells for immunofluorescence assay.  (I, II) 
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BDV isolation from rodent samples was attempted as described above in Vero E6 cells, 
and in addition, in the following cell lines: rat astrocyte C6, mouse neuroblastoma 
Neuro-2A, human neuroblastoma SK-N-SH, and in primary rabbit embryonic brain 
(REB) cells. REB cells were prepared from newborn, guillotine-killed rabbits by 
first suspending the brain with a mortar and pestle in cell culture medium and then 
homogenising the suspension with a 20G needle and syringe before inserting into 
laminin-coated (1.2 μg/cm2) cell culture flasks. The cells were grown in 10% FCS-
containing Dulbecco’s modified Eagle’s medium for about one week into 40–90% 
confluence before infection with 10% brain suspension as described above, and split 
once or twice 1:2. If the cells grew well, the FCS concentration was reduced to 5%, 
and if not, they were assisted with addition of 2–5 μg/ml laminin, and supplemented 
with fresh REB cells. within a few weeks, before or when the REB cells stopped 
dividing, VeroE6 cells were introduced into the flasks. They rapidly overwhelmed 
the REB cells. The cultivation was continued as described above for 3–4 months. 
(Kinnunen et al. unpublished)
4.3.2 Experimental animals
A 20 μl volume of 10% or 1% tissue sample homogenate from OPV-PCR-positive 
rodents was injected intracerebrally (i.c.) into newborn NMRI mice within 24h of 
their birth. The mice were monitored daily and euthanized by cervical dislocation 
under isoflurane anaesthesia on day 6 p.i. The brains were collected and stored at 
-70 °C, followed by later homogenisation with 5000 rpm on the MagNAlyser 
instrument (Roche) using ceramic beads as a disruptor. Nucleic acids were extracted 
from the brain homogenates with a Viral DNA Mini kit (Qiagen) and OPV PCR was 
performed (see below). (II) 
4.4 electron microscopy
Samples from the cowpox patient and virus isolation were dispensed on Formvar-carbon 
coated grids and negatively stained for 10–20 s with potassium phosphotungstate (2%, 




4.5.1 Immunof luorescence assay and avidity measurement
CPXV and other, cross-reacting, OPV-specific Ig(G)-antibodies were detected with an 
immunofluorescence assay (IFA) based on acetone-fixed, CPXV/FIN/T2000-infected 
Vero cells mixed with uninfected cells 1:10 as a simultaneous control (I, II). Titres 
of >20 for serum and >10 for whole blood were used as the cut-off. Some of the first 
results were also verified with a haemagglutination inhibition test. 
BDV-specific antibodies were similarly measured with IFA based on persistently 
BDV/He80-infected, acetone-fixed C6 cells and uninfected C6 cells 1:2 (III, IV). 
Serum samples with a mean titre of >15 and blood samples with a titre of >10 were 
classified as positive. CSF samples were studied as undiluted. Preparation of BDV–IF 
glasses was optimised by changing several parameters and trying different treatments: 
the frequency and ratio of cell splitting before preparing the IF glasses, IF glass 
materials and treatments, fixation and permeabilization agents and duration, antigen 
denaturation with 8-M urea, and the ratio of infected and uninfected cells. Cultivation 
for one week before pipetting of one part of the infected together with two parts of the 
uninfected cells onto Teflon-coated 10-well glasses followed by 20 min fixation and 
permeabilization with acetone produced the best results.
Avidity measurement was used for estimating the age and specificity of antibody 
responses (139, 283). The avidity index (AIX) was calculated as (IFA titre with 6-M 
urea wash)/ (IFA titre without urea wash) x 100% (37), and antibodies with AIX > 
25% were interpreted as highly avid (I-III).
4.5.2 Verif ication of BDV antibody f indings: recombinant antigens and 
peptide arrays
The most important BDV-IFA results were verified with other, independent methods. 
Recombinant BDV N and P antigens were produced as glutathione S-transferase fusion 
proteins in Escherichia coli (35), and constructed and produced in the baculovirus 
expression system in Spodoptera frugiperda (Sf9) insect cells (290), also used by (347). 
Recombinant antigens served in immunoblotting and Sf9 cell-based IFA for antibody 
detection (the appendix of III). Furthermore, epitope mapping using a peptide array 
covering the coding regions of BDV N and P genes was carried out (37) (The appendix 
of III). 
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4.6 worK w ith genetic material
4.6.1 Controlling the contamination risk
Extremely strict care was taken in avoiding contamination of samples by one-way flow 
through three to five separate laboratories and two buildings (II-IV). Finnish samples 
were stored and handled, and master mixes pipetted at special laboratories of the 
Faculty of Veterinary Medicine. For sample handling, workers dressed with particular 
protective clothes. Only highly diluted positive controls (RNA from 0.005–50 BDV/
He80-infected cells, 120 copies of partial VACV HA gene for CPXV) were used in 
a laboratory different from the samples (II-IV). DNA, cDNA or the first PCR round 
amplicon were transported in tightly closed tubes 5–8 km to the Haartman Institute, 
where sample processing continued in separate laboratories wearing distinct protective 
clothes (II-IV). In all laboratories, detergent disinfectants and ultraviolet light were 
employed before and after any sample, reagent or control handling; only filter tips 
were used; and gloves were frequently changed.
4.6.2 Sample homogenisation and nucleic acid preparation
Tissue samples were homogenised with a mortar and pestle (I-III), Tissue Lyser 
(Qiagen; II) or in a MagNAlyser instrument (Roche; IV). Nucleic acids were extracted 
either manually with the Tripure kit (Roche; I, III, IV), the AllPrep DNA/RNA Mini 
kit (Qiagen; II, IV), or the High Pure PCR Template Preparation kit (Qiagen; II); or 
employing automatons using the MagNApure total nucleic acid kit (Roche; II) or the 
NucleoSpin 96 Virus Core kit (Macherey–Nagel; II). Nucleic acids were used as fresh 
or after storage for a few days at +4 °C (DNA) or longer at -70 °C.
For BDV PCR (III), fresh blood samples with ethylenediaminetetra-acetic acid 
(EDTA) as the anticoagulant were stored with 10% volume of dimethyl sulfoxide 
(DMSO) at -70 °C and RNA was later extracted from leucocytes with the Qiagen 
RNA Blood kit. Samples older than two days were stored as such at -70 °C and RNA 
extracted from 100 μl of whole blood with the Tripure kit (Roche).
4.6.3 PCR
Parts of the genomic OPV DNA were amplified with several PCRs (Table 5). 
These targeted the haemagglutinin gene (artus Orthopox LC PCR kit, Qiagen, 
and (73, 253, 265)) coding for a membrane protein related to viral entry (74, 218); 
the thymidine kinase gene (270), the product of which is involved in the synthesis 
of deoxyribonucleotides to enhance DNA replication in cells and located within 
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the conserved part of the genome (74, 218); the A-type inclusion body gene (213) 
located within the conserved part of the genome and encoding with high capacity the 
inclusion protein (74, 218) (I, II); as well as the 14 kDa (fusion) protein gene (234, 
274) (II), the product of which belongs to a putative entry complex (74, 218).
RNA from BDV samples was reverse transcribed and amplified with primers 
annealing to the nucleotides 210–227 and 585–606 (outer round), and to 229–247 
and 462–483 (inner round) of the BDV/He80 N gene sequence (Table 5; III, IV). 
In addition, methods for amplifying the P gene of BDV were utilised (34, 341) (IV). 
BDV-specific DNA was amplified with the methods described above without the 
revere transcription step. For some highly interesting samples, degenerated primers 
were planned and used to specifically anneal to the conserved transcription start and 
termination sites of BDV strains (S2, T2; Table 5) (249), but they proved insensitive 
(Kinnunen et al. unpublished).
None of the PCR methods were used in quantification of the target gene, i.e. 
normalised to a host gene and compared with a standard curve, but the methods were 




























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































4.6.4 Sequencing and sequence analysis
The amplicons were purified with the Qiagen Gel Extraction kit (I, II), the Qiagen 
PCR Purification kit (I and Kinnunen et al. unpublished) or the enzymes Exonuclease 
I and SAP (Fermentas; IV). The resulting DNA was cycle sequenced in both directions 
with Big Dye Terminator reagents (Applied Biosystems) in an ABI 3130xI capillary 
sequencer device (I–IV).
Forward and reverse sequences were checked against each other and verified by the 
chromatograms. Then they were analysed with the BioEdit program (http://www.
mbio.ncsu.edu/bioedit/bioedit.html) with a further search for matches using BlastN 
(http://blast.ncbi.nlm.nih.gov) (I, II, IV), and alignment using ClustalX (http://www.
clustal.org), continued by maximum likelihood analysis with the software TREE-
PUZZLE (http://www.tree-puzzle.de), the results of which were compared to those 
from the programs of the PHyLIP package (http://www.phylip.com) (I, Kinnunen et 
al. unpublished).
4.6.5 Verif ication of DNA findings
BDV DNA findings were verified by comparing the PCR results with and without 
previous template digestion with DNAse and RNAse (IV).
4.7 histology anD immunohistology
Paraffin-embedded, formalin-fixed tissue samples were subjected to histological 
haematoxylin-eosin staining and immunohistological staining with a 1:5000 dilution 
of polyclonal rabbit anti-BDV-N or, as a control,  preimmune antibody (164), mouse 
monoclonal anti-N antibody Bo18 1:100 (121) or a polyclonal rabbit anti-BDV-P 
antibody 1:20 000 (164). The staining was performed utilising the avidin-biotin-
peroxidase system (185) either manually, including an antigen retrieval step with 
protease and an overnight incubation at +4°C ((141); Kinnunen et al. unpublished), 
or in a Ventana Discovery Automatic Slidestainer (Ventana Medical Systems; IV). 
Cleaved caspase-3 expression was demonstrated according to a previous protocol (161).
4.8 experimental infection of BanK voles
Thirteen bank vole dams, which were originally born to wild-caught parents 
trapped by researchers at the University of Jyväskylä, and their 50 pups participated 
in the BDV infection experiment in the biosafety 3 level laboratory of the Faculty 
of Veterinary Medicine (IV). They were maintained under negative pressure in 
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individually ventilated, high-efficiency particulate air (HEPA) filtered cages (Isocage 
Unit, Tecniplast, Italy), the function of which was checked daily. The pups were 
infected i.c. with 102, 103 or 104 focus-forming units (ffu) of the “rat BDV” (303), or 
PBS as a control, and monitored daily until euthanasia at 2, 4, 6 or 8 weeks p.i. The 
cages were opened and animals handled in a biosafety changing station (Tecniplast, 
Italy) behind HEPA-filtered laminar flow.   
Blood samples, and when possible, urine, were collected from live animals at the end 
of the study. Other samples, such as brain, organs, faecal-filled rectum (at least four 
times more faeces than tissue), and sometimes additional urine, were sampled from 
fresh carcasses, and stored for further use in immunohistology and PCR studies with 
the methods described above. (IV)
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5. r esults anD Discussion
5.1 assays estaBlisheD for cpx v anD BDv 
Detection
Several methods for the detection of CPXV/OPV and BDV infections in various 
samples of animal and human origin were either set up according to the literature 
or designed and established. Of these, virus isolation as the ultimate proof of a viral 
infection was first set up. A functioning cell culture method for CPXV isolation 
with electron microscopic confirmation was established (I, Fig. 8), although it was 
insensitive to vole samples (II). Furthermore, numerous methods, such as neuronal 
cell lines and primary REB cells, were set up and used for BDV isolation attempts 
(Kinnunen et al. unpublished). 
Figure 8. Electron micrograph of the CPXV isolate FIN/T2000 originating from a cowpox 
patient. (Original figure: Inki Luoto, HUSLAB, Helsinki; with permission.) 
Secondly, immunofluorescence assays (IFA) based on the newly isolated Finnish 
CPXV isolate T2000 and the BDV strain He80, as well as BDV recombinant antigens 
N and P, were established for OPV / BDV antibody detection from blood, serum 
and CSF samples of humans and animals (I, III). The IFA method was enriched to 
include the measurement of antibody avidity in order to differentiate acute from past 
infections, and also to assess the specificity of BDV antibody findings (I, III). For 
further verification of BDV antibody results, immunoblotting and peptide arrays were 
set up (III). 
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Thirdly, several conventional and real-time PCRs including sequence analysis (but 
not quantification) were established to detect CPXV and BDV genes in human 
and animal tissues and excreta (Table 5) (I–IV). The primers for the nested BDV 
PCR targeting the N gene were planned to anneal to all available BDV sequences 
at the time of establishment, including the most variable No98 subtype (228). The 
repeatable sensitivity of that newly established method was 1/160 of a persistently 
BDV-infected cell and 1 spiked infected cell in 90 μl of feline blood (Fig. 9). Although 
sensitive for BDV control strains, the primers are not necessarily optimal for other 
deviant bornaviral sequences; for example, they do not detect the recently found ABVs 
(176) in silico. A typically low BDV amount in infected tissues comprises a further 
challenge. In this study, this biological fact was controlled by detecting the two most 
abundantly transcribed genes and the corresponding mRNAs, N and P, with high 
sensitivity (34, 341) (Fig. 9; III). Taken together, the BDV PCR methods employed 
were the best available when the study was conducted. In addition, exceptional care 
was taken to prevent possible contamination (49).
Figure 9. The BDV RT nested PCR is sensitive: 1/160 of a BDV-infected cell is enough to 
detect N gene RNA.
As the fourth type of detection method, immunohistology was established to 
evaluate the viral distribution and for the detection of a Finnish BDV variant 
possibly escaping PCR methods (IV). It is the most common technology used for post 
mortem confirmation of BDV infection in animals (271), and may also detect slightly 
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divergent virus variants without any risk of contamination. In some animals with overt 
neurological disease, however, only very few antigen-positive cells can be visualized, 
which indicates that BD can sometimes escape detection by immunohistology (57).
The most relevant methods for CPXV and BDV detection and diagnosis were established 
(I-IV). In addition to assays recognizing viral nucleic acids, viruses, and viral antigen 
(BDV), methods detecting antibodies and the avidity of antibodies became available. 
The employment of several independent methods is especially important for BDV 
infections, the detection of which has been hampered by contradictory results (194, 
271). This is why special care was taken concerning specificity issues, probably at the 
cost of sensitivity. For instance, although IFA is considered the most reliable method 
for BDV antibody detection (reviewed by (299)), it may be 10x less sensitive than 
ELISA, and their BDV results do not always correlate in naturally infected cats (164). 
Many factors were noted to affect the IFA results: in addition to unknown factors, the 
fixation and permeabilization conditions, as well as the time from the splitting of cells 
played a role. BDV prevalences based on the IFA are most probably underestimated, as 
not all positive control sera from Germany and Sweden were positive, but all negative 
controls were negative. Some of the control sera from verified Borna diseased horses 
in Germany repeatedly gave positive IFA results with a 1:10 dilution only, so the cut 
off of 1:15 for serum was chosen. Previously reported cut-offs for IFA have varied from 
1:5 to 1:20 (271, 321). Unfortunately, no serum panel originating from individuals 
detected as BDV-positive or -negative with verified, agreed methods, exist for exact 
validation of the sensitivity and specificity of any assay (271). Hence, to classify a 
sample as verified positive, we employed additional methods (avidity measurement, 
recombinant antigens, and peptide array) or repeated sampling, or both. The ultimate 
aim was to determine whether verifiable infections with BDV or a closely related 
agent exist in the target species and regions instead of studying seroprevalence with 
optimised sensitivity. For this purpose, the IFA, combined with the other serological 
methods, worked well.
The sensitivity of OPV IFA proved good when compared to the results from another 
IFA utilising CPXV-infected and uninfected rodent sera from Great Britain (Kinnunen 
et al. Unpublished), as well as vaccinated and unvaccinated human sera (I, Fig. 10). 
For cow samples, however, the method was not ideal, as a high proportion (but not all) 
of cattle sera showed unspecific reactivity to Vero cells. These samples were discarded 
from the analysis. A strict cut-off was applied for both IFAs: as compared to those 
classified as positives, at least the same (OPV) or double (BDV) the number of unclear 
results was seen and interpreted as negative.
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Figure 10. An orthopoxvirus (OPV) IFA based on cowpox virus strain T2000-infected and 
uninfected (~1:10) Vero cells detects OPV-IgG antibodies in the serum of a vaccinia virus-
vaccinated (A) but not of an unvaccinated person (B). Original magnifications 400x.
Avidity measurement, in addition to IgM detection, is a valuable tool in the timing 
of primary infections in humans (139, 140). However, it could also be studied and 
utilised more on animals, as the diagnosis could be made earlier instead of waiting 
for the paired serum sample. To validate the method properly for each pathogen and 
species, serial serum samples should be studied from experimentally infected animals, 
similarly to a study on the response of bank voles to hantavirus (112), or from a well-
known outbreak (19). In the OPV avidity assay, the results were as anticipated: those 
vaccinated or infected months or years ago had highly avid antibodies, whereas in 
acutely ill or clearly PCR-positive individuals or both, low avidity (or absence of 
antibodies) was seen (I, II). Since the findings of the BDV avidity assay could not 
be compared to the findings of methods detecting nucleic acid, antigen or virus (see 
“5.5 A few mammal species harbour BDV antibodies in Finland”), they remain 
preliminary, although individuals with both kinds of antibodies, either with high or 
low avidity, were reliably detected (see later; III). Nevertheless, a high avidity of BDV 
antibodies can be interpreted as additional proof of a specific reaction (8, 37), and was 
thus used as a verification method for the presence of BDV infections in Finland. 
5.2 cpx v can cause severe infection in 
unvaccinateD atopic chilDren
Clinical samples from a few suspected cowpox patients were investigated. CPXV 
infections could be verified from two human patients by virus isolation, PCRs and 
sequencing (I). In a four-year-old, unvaccinated atopic girl from eastern Finland, 
cowpox (isolate T2000) manifested as severe, smallpox-resembling, generalised 
dermatitis necessitating one week of hospitalisation but resulting in a favourable 
outcome after some weeks (Fig. 11; I). This was the first verified cowpox case in 
Finland and proved the existence of CPXV in Finnish fauna. After that, a dermatitic, 
a B
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17-year-old female patient from southern Finland was diagnosed from an archive 
lesion sample, dating back to 1989, to have suffered from cowpox (I, Kinnunen et 
al. Unpublished). This CPXV isolate was designated E1989. Both patients contracted 
cowpox in autumn, when the majority of cases have also been diagnosed in Great 
Britain and Germany (23, 172). 
Figure 11. Cowpox lesions on a patient’s back and upper arm seven days after the onset of 
symptoms. Photo: Kyllikki Tarvainen, with permission.
The female gender and young age of both the patients were unsurprising: 26% of 
cowpox cases have occurred in children <12 years old and 20% in young girls (22). 
Although cowpox usually manifests as one or two skin lesions also in children (23), 
people specifically suffering from atopic dermatitis or allergic rhinitis have had severe 
generalised cowpox eruptions resembling that of the Finnish girl ((40, 154); reviewed 
by (23)). Similarly to the Finnish case, some difficulties have arisen before making the 
correct diagnosis, and the lesions in these patients have likewise recovered uneventfully 
in around four weeks after the onset of the symptoms. The infection source has 
remained unresolved in 46% of the cases (23), but most often contact with a sick 
rat (154) or cat (40) has been suspected or proven (see the literature review). The girl 
from southern Finland owned a cat, which was antibody-negative when the patient’s 
disease was acute (Kinnunen et al. unpublished). In the case from eastern Finland, the 
girl had played with a dead bat, which was not available for the studies, but two dogs 
of the family showed an OPV antibody response (I; Table 6). As expected, the dogs 
were healthy at the time of clinical examination, several months after the disease in 
the girl. OPV infection in dogs seems to be rare, as few previous and only one recent 
report are available (291, 326, 327). Overall, OPVs are not apparently very pathogenic 
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to carnivores, as evidenced by the mildness of the natural canine and experimental 
fox infections (50). Thus, a dog had most probably transmitted the virus from an 
unnoticed lesion, although the role of the bat or direct contact to rodents or their 
excreta could not be excluded. No published evidence exists on CPXV infection in 
bats. 
5.3 opv antiBoDies are r are in younger age 
groups
To assess the OPV antibody prevalence in different age groups in Finland, 
138 veterinarians were sampled during the Annual Veterinary Conference 
(Eläinlääkäripäivät) 2001. A lower OPV antibody prevalence in younger age groups 
was seen in the panel (I and Fig. 12).  This corresponds well with the gradual cessation 
of smallpox vaccination with VACV, which is cross-reactive and -protective against 
CPXV in addition to smallpox virus. In those born in 1972 or later, the prevalence 
and thus protection could be seen in less than 18% of the individuals, indicating an 
increasing susceptibility to cowpox and any OPV infection.  (I)
Figure 12. Orthopoxvirus antibody prevalence (%) in veterinarians in 2001 according to 



















In addition to reflecting the cessation of VACV vaccinations, these results indicate 
that at least two seropositive individuals in the youngest age group had most probably 
responded to natural CPXV infection, as the last VACV vaccinations were carried out 
in 1977 when even the oldest individuals in that group were too young to be vaccinated: 
the recommended age for the first vaccination has been one to two years (79). These 
findings were rechecked with veterinary samples collected in 2009 showing that the 
overall prevalence had decreased as expected, because later age groups had entered the 
veterinary profession (Kinnunen et al. unpublished). Again, some antibody responses 
seemed to arise from natural infection instead of vaccination. The average population 
without frequent animal contact may even have a lower OPV antibody prevalence and 
is therefore vulnerable to cowpox, and in the improbable case of a deliberate release, 
to smallpox. This emphasises the importance of public awareness, at least among 
people with atopic diseases who are therefore prone to severe manifestations, and 
among veterinarians, who frequently encounter sick cats or their samples. Fortunately, 
cowpox was nominated as an immediately notifiable animal disease and immediately 
notifiable zoonosis in the veterinary legislation in 2010. Veterinarians are, indeed, the 
key players in inhibiting zoonotic transmission from domestic animals to humans, 
including themselves. 
Orthopoxvirus protection usually lasts long after vaccination: more than 90% of people 
vaccinated 25–75 years ago still maintain substantial immunity against VACV ((130); 
reviewed in (74)). The antiviral antibody response remained stable 1–75 years post-
vaccination, whereas antiviral T-cell responses declined with a half-life of 8–15 years. 
whether the cessation of smallpox vaccination campaigns will lead to an increased 
OPV disease incidence has long been discussed, and some researchers hypothesise that 
VACV vaccinations provide only limited and uncertain protection against cowpox 
(22). However, the increasing OPV disease incidence assumed elsewhere (330) has 
now been proven: the cumulative incidence of monkeypox increased 20-fold from the 
1980s to the years 2006–7 in the Democratic Republic of Congo, where unvaccinated 
persons have a 5.2-fold higher risk of monkeypox than vaccinated persons. The 
incubation time and severity of cowpox symptoms have also been associated with the 
patient’s VACV vaccination status in the family: two unvaccinated girls had multiple 
lesions accompanied by local lymphadenopathy and fever after only 3 and 5 days of 
incubation (55). In contrast, the incubation period for three VACV-vaccinated adults 
was longer than 7 days, and they presented with a single small lesion without any other 
symptoms. A similar, milder clinical picture has been described in a vaccinated man 
(68). These cases indicate that VACV vaccination conveys partial protection against 
CPXV, but they are too few to draw final conclusions.  
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5.4 w iDe mammal spectrum harBours opv 
antiBoDies in finlanD
The presence of OPV infections was examined with IFA screening of hundreds of 
blood samples from vertebrate animals resident in Finland. In the cat, dog, horse, 
cow and lynx, antibodies to orthopoxviruses (including CPXV) were detected (I, 
Kinnunen et al. unpublished; Table 6). Most of the OPV antibody-positive animals 
lived in southern Finland, and the antibody avidity was high in the majority of the 
samples, indicating infection weeks to years ago (data not shown). 
The large host spectrum is different from that of other poxviruses but typical of 
CPXV (98). However, it was noteworthy that horses commonly had OPV antibodies 
(3.1%). The most probable explanation would be subclinical infection after exposure 
to wild rodents or their excreta. Nevertheless, it cannot be excluded that infected 
horses become sick. Are some of the mysterious skin lesions occasionally encountered 
in horses caused by CPXV? A single clinical cowpox case in a horse has been verified 
in Germany this century (243). The patient suffered from papular dermatitis all over 
the body, crater-like tongue and mucosal lesions, purulent conjunctivitis, anorexia and 
apathy. Full recovery was, however, rapid, taking only a few days. Remarkably, no 
other horse or other animal in the circus where the horse came from became sick, and 
as this is the only report of cowpox in horses, it should be regarded as an exception 
probably based on individual predisposition. In the 19th century, however, so-called 
horse-pox was common in horses but later disappeared (197). It was a generalised, 
three-week-long dermatitis, which was contagious to other animals and man, in the 
latter resembling smallpox vaccination lesions. 
The finding of OPV infections in lynxes verified previous results obtained from a more 
sensitive but possibly not so specific method, competitive ELISA (314). In the previous 
study, 1 of 73 Finnish and 5 of 17 Swedish lynxes harboured OPV antibodies, so the 
prevalence in Finland has remained the same (currently 1.4%). The seropositive lynxes 
were hunted in eastern Finland, one of them even in the very municipality in which 
the human cowpox case was detected. wild carnivores seem to be susceptible to the 
infection and respond to it by producing antibodies, as also evidenced by experimental 
(50, 51) and natural infection of foxes (208, 314) and a brown bear (314). 
In addition to western and eastern Finland, OPV infections were common in cats 
living in the capital region (up to 13.7%). In Great Britain, 32% of the cats with 
verified cowpox virus infection also lived in suburban or urban environments (31). 
For a small proportion (8/16) of the seropositive individuals from the capital region, 
the descriptions (signalement) were available. Six of them were males and two females, 
the median age was 8.5 years and all but one represented mixed breeds. Seven cats 
lived in Helsinki and one in nearby Espoo; at least four of them were from locations 
where cats are commonly left to roam free in a semi-urban environment. The rest had 
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probably acquired the infection either at other habitats or during a stay at a summer 
cottage. Five of the cats had become infected in the past, as their antibodies had 
high avidity, whereas three cats presented with low-avid antibodies indicating a more 
acute infection. The probably acutely infected cats had been sampled in May, October, 
and November, all months with a known cowpox incidence (172). No clinical data 
were available from these cats, but these findings emphasise the importance of also 
remembering cowpox as a differential diagnosis in cities, and consequently sampling 
skin and mucosal lesions for OPV detection. As cats are the most common infection 
source for humans (23), clinical suspicion and a specific diagnosis are important to 
prevent zoonotic transmission. During this study, only one clinical suspicion was 
apparent, but the cat was PCR- and antibody-negative, and later proved to have T-cell 
lymphoma (Kinnunen et al. unpublished). Previous cat studies from other countries 
have revealed OPV antibody prevalences of 0–2% in Great Britain (31, 111, 345), 
0.46–10% (lower prevalence with IFA, higher with competitive ELISA) in Norway 
(316), 0.41–13% in Germany (208, 225, 349), and 2% in Austria (225). In addition to 
the geographical distribution of feline CPXV/OPV infections, prevalence differences 
may be explained by the different methods used: competitive ELISA seems to be 
considerably more sensitive than IFA (316), and haemagglutination inhibition is 
slightly more sensitive than the virus neutralization test (29, 111). No previous data 
are available on the development of OPV antibody avidity or the longevity of IFA 
antibodies in cats. If, as is probably the case, they reflect those from humans (I; (130)), 
and those detected with other methods in cats (from 6–16 days post infection (dpi) 
onwards, for a minimum of 6 months; (29, 32, 111)), the low-avid antibodies would 
indeed be a sign of an acute infection and the antibodies would remain for months to 
years, even decades, after infection. Thus, the high OPV seroprevalence in cats (Table 
6) would reflect the proportion of cats that had encountered a CPXV infection 6 days 
to years previously.
Interestingly, one cow was seroreactive to OPVs (Table 6). The cow originated from 
a large farm in southern Finland, some cows from which presented acute farmyard 
pox lesions (parapoxvirus infection) at the time of sampling. Since the antibodies 
did not correlate with parapoxvirus findings, they are indicative of the exposure of 
Finnish cattle to OPVs in addition to the better known farmyard pox. Further studies 
are needed to assess the clinical relevance of this preliminary finding, but as the last 
reported clinical cowpox cases in cattle date back to the 1970s and happened at a farm 
with poor milking hygiene and udder health (114), the relevance most likely remains 
exiguous.
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Table 6. Orthopoxvirus antibodies in large Finnish mammals as detected by 
immunofluorescence assays using cowpox virus as the antigen.
Panel n OPV 
positive
Prevalence, % CIs for 
prevalencea
Publication
Cat, total 213 21 9.9 6.21 – 14.7
From the same 
farm as a  cowpox 
patient
1 0 0 Unpublished
Southern Finland 117 16 13.7 1.91 – 10.8 Unpublished
Stray cats in the 
capital region
77 3 3.9 0.811 – 11.0 I
western Finland 6 1 17 0.421 – 64.1 Unpublished
Eastern Finland 12 1 8.3 0.211 – 38.5 Unpublished
Dog, from same 
farm as a cowpox 
patient
3 2 67 9.43 – 99.2 I
Horse, total 223 7 3.1 1.27 – 6.36
From same farm 
as a cowpox 
patient
1 0 0 I
Southern Finland 111 5 4.5 1.48 – 10.2 I, Unpublished
western Finland 8 0 < 13 0.0 – 36.9 Unpublished
Åland Islands 12 0 < 8.3 0.0 – 26.5 I
Northern Finland 12 0 < 8.3 0.0 – 26.5 Unpublished
Eastern Finland 79 2 2.5 0.308 – 8.85 I
Rabbit, from the 
same farm as a 
cowpox patient
1 0 0 I
Cattle 12 1 8.3 0.211 – 38.5 Unpublished
Lynx 145 2 1.4 0.167 – 4.89 Unpublished
Wolf 3 0 <33 0.0 – 70.8 Unpublished
a 95% confidence intervals, Fisher’s exact test
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5.5 a few mammal species harBour BDv  
antiBoDies in finlanD
IFA screening of more 1500 blood samples was used to investigate the presence of 
BDV infections in vertebrate animals resident in Finland. BDV-specific antibodies 
existed in cat, dog and horse blood samples, the highest prevalences being in stable 
mates of other seropositive horses and in recently imported horses, which were sampled 
for statutory equine infectious anaemia screening, as well as in neurobehavioural cat 
and horse patients (III, Kinnunen et al. unpublished; Table 7).  Most seropositive 
horses and one of the two cats had high-avid antibodies, and furthermore, most IFA 
findings were verified with either a peptide array or recombinant antigens, or both 
(III). Although BDV antibodies were more commonly found in neurobehaviourally 
symptomatic horses and cats than in other animals, no significant correlation with the 
symptom status could be seen. Instead, stable mates of BDV-antibody positive horses 
had a significantly greater risk of being seropositive as compared to horses without 
such contact (p = 0.0097, Mid-P exact test), indicating exogenous infection from 
either each other or a common source rather than some kind of activation of cross-
reactive antibodies. Interestingly, one symptomatic, BDV-antibody-positive horse 
had previously eaten oats from the very field where a BDV-antibody-positive root/
tundra vole (Microtus oeconomus) was trapped suggesting but not proving a possible 
transmission chain (III). Previously, a prevalence of 33% has been found in horses 
from stables with a history of Borna disease (148, 260). 
Like horses, a close proximity to BDV-antibody positive horses was a risk factor for a 
dog to also be BDV-antibody-positive (p = 0.01630, MidP exact test). The only dog 
presenting with antibodies was a clinically healthy hunting dog, whereas none of the 
neurobehaviourally symptomatic dogs had antibodies. Although BD can affect dogs, 
the infections and disease appear rare (232, 338). 
In contrast to reports from Sweden, BDV infections were not found among Finnish 
birds or lynxes (36, 84). Furthermore, BDV infections did not exist or existed with 
low prevalence in sheep and cattle.  Overall, the BDV antibody prevalences from 
serum were the same as or lower than elsewhere based on IFA: 2.7% in American 
and 29–100% in German horses (169, 260, 320); 16% in German sheep (320); and 
7–34% in German and 17–44% in symptomatic Swedish cats (157, 196); reviewed 
in (158, 167). In these previous studies, species panels mainly much smaller (5–295 
animals, median 27.5) than in the current study have been analysed, thus giving more 
influence to chance. In addition to IFA, BDV antibodies have also been detected with 
other serological methods, but as the results are quite incomparable with each other 
(110, 164, 168, 271), comparison of prevalences makes no sense.  
Notably, BDV antibodies can only be found in the sera of 30–40% of verified, infected 
animals (119, 164, 171, 321), so these seroprevalences are clearly an underestimate 
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of the existing BDV infections. One explanation for the common lack of detectable 
antibodies could be the complexing of the antibodies with the corresponding 
circulating antigen (47), but as the existence of antigenaemia has been questioned 
(343), the special biology of BDV – the tight association with cells, neurotropism, 
persistence, and noncytopathogenicity – remains the most probable explanation for 
this kind of immune evasion (303).
Table 7. Borna disease virus (BDV) antibodies in large Finnish vertebrates as detected by 
immunofluorescence assays using BDV strain He80 as the antigen.







Cat, total 323 2 0.62 0.075 – 2.22
Stray cats in capital 
region
74 0 < 1.4 0.0 – 4.86 III
Southern Finland 126 0 < 0.8 0.0 – 2.89 III, 
Unpublished
western Finland 3 0 < 33 0.0 – 70.8 Unpublished
Eastern Finland 12 0 < 8.3 0.0 – 26.5 III
Healthy cats, all 
Finland




293 1 0.34 0.008 – 1.89
Neurological / 
behavioural patients, all 
Finland
30 1 3.3 0.084 – 17.2 III
Dog, total 92 1 1.1 0.027 – 5.91
From the same farm as 
a BDV-positive horse
3 1 33 0.84 – 90.6 III
Neurological symptoms 89 0 < 1.1 0.0 – 4.06 III
Horse, total 608 12 1.97 1.02 – 3.42
Southern Finland 83 0 < 1.2 0.0 – 4.35 Unpublished
western Finland 20 0 < 5.0 0.0 – 16.8 Unpublished
Åland Islands 12 0 < 8.3 0.0 – 26.5 III
Northern Finland 18 0 < 5.6 0.0 – 18.5 Unpublished
Eastern Finland 85 2 2.4 0.286 – 8.24 III, 
Unpublished
Recently imported 93 3 3.2 0.671 – 9.14 III, 
Unpublished










or contact with BDV 
patient, total
486 6 1.23 0.454 – 2.67
Neurological /
behavioural patients
108 4 3.70 1.02 – 9.21 III, 
Unpublished
From the same farm as 
a BDV-positive horse
14 2 14 1.78 – 42.8 III
Cattle 52 0 < 1.9 0.0 – 6.85 III
Sheep 22 0 < 4.6 0.0 – 15.4 III
Lynx 145 0 < 0.69 0.0 – 2.51 III
Wolf 3 0 < 33 0.0 – 70.8 III
Bird, grouse 292 0 < 0.34 0.0 – 1.26 III
a 95% confidence intervals, Fisher’s exact test
PCRs did not amplify specific nucleic acids from the skin biopsy of the single cowpox-
suspected cat (Kinnunen et al. unpublished), or from any of the 134 whole blood or 
4 brain samples of the BDV-studied horses or cats (III). It is exceptional to obtain 
proper tissue samples from clinicians for virus detection: brain for BDV and lesion 
biopsies or organs for CPXV. The lack of samples most probably explains why no 
PCR-positive patients were found in this study. On the other hand, a few BDV-
antigen-positive animal brains have been detected among archived samples (Fig. 13) 
((141) and Kinnunen et al. unpublished). Moreover, a transient BDV infection of REB 
cells inoculated with a cerebrocortical sample from an equine patient could be seen 
(240), although infectious virus could not be demonstrated in the (few) other animal 
samples. Difficulties in the isolation of BDV despite common antibody findings may 
be related to the markedly low level of virus production conveyed by the genome 
trimming strategy affecting viral but not RNA and protein amounts (279). BDV 
isolation has also previously proven demanding because BDV multiplies very slowly, is 
strictly neurotropic and, in the infected tissue, often has a very low titre (76, 118, 186) 
(and the review by (299)). However, BDV infections of many host species were proven 
by serological methods in this study, and two parallel studies also detected antigen 
(Fig. 13) and/or virus. 
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Figure 13.  An atactic cat with nonpurulent encephalitis expressing Borna disease virus 
(BDV) but not Puumala virus antigen in the cerebrum (arrowheads). Immunohistological 
staining with polyclonal rabbit antisera against glutathione S-transferase (GST) fusion 
proteins of (A) Puumala virus nucleocapsid protein (negative control) 1:5000, (B) BDV 
nucleocapsid protein 1:5000 and (C) BDV phosphoprotein 1:10 000. Magnification 400 x.
5.6 opv antiBoDies are common anD BDv 
antiBoDies occasionally founD in eur asian w ilD 
roDents
To find out hosts and possible reservoir species of CPXV/OPV and BDV infections 
and to elucidate their geographical distribution, more than 2000 wild small mammals 
from Finland, Germany and Buryatia, Russian Siberia, were sampled and studied for 
viral antibodies with IFA. wild rodents had commonly had contact with OPVs in 
Eurasia: antibody-positive individuals were found in all three regions and in almost all 
parts of them (I, II, Table 8). The prevalences varied locally from 0% to as high as 92%, 
which was seen in one population in southern Finland (I). The few studied insectivores 
from Finland and Germany did not have OPV-specific antibodies (data not shown, 
Kinnunen et al. unpublished). Most of the seropositive rodents were bank voles, a 
well-known host for CPXV. However, especially in regions other than Finland, other 
known hosts, the field vole (Microtus agrestis), root/tundra vole (Microtus oeconomus), 
and gray red-backed vole (Myodes rufocanus) also harboured antibodies. In addition, 
three new CPXV/OPV host species were detected: the striped field mouse (Apodemus 




Table 8. Orthopoxvirus antibodies in Eurasian wild rodents as detected by 








Finland, total 1445 142 9.83 8.34  – 11.5
South 295 82 27.8 22.8  – 33.3 I, II
west 649 52 8.01 6.04 – 10.4 I, II, 
Unpublished
North 465 7 1.51 0.608 – 3.08 I, 
Unpublished
East 36 1 2.78 0.070 – 14.5 I
Germany, total 224 71 31.7 25.7 – 38.2
Nordrhein-
westfalen
27 0 < 3.7 0.0 – 12.8 II
Mecklenburg-
Vorpommern
47 15 31.9 19.1 – 47.1 II
Sachsen-Anhalt 150 56 37.3 29.6 – 45.6 II
Buryatia, total 437 14 3.20 1.76 – 5.32
Central 168 7 4.17 1.69 – 8.40 II
South 269 7 2.60 1.05 – 5.29 II
a 95% confidence intervals, Fisher’s exact test
In these samples, OPV was more prevalent in Germany than in Finland or Buryatia 
(Table 8; II, Unpublished). As the rodents from different locations were not trapped at 
the same time, and the sampling was not planned to evenly represent whole countries, 
the figures are not completely comparable. These regional prevalence differences, 
however, are clearly statistically significant (p < 0.00001) further clarifying the 
fact that although generally present, CPXV displays considerable regional (96) and 
seasonal (63, 138) fluctuation in prevalence based on population demographical 
factors (25, 26). 
The OPV species responsible for the antibody findings cannot be defined on a 
serological basis alone due to their cross-reaction. OPVs other than CPXV are not 
known in Eurasian wild rodents, although they occasionally infect rodents of Africa, 
North and South America (2, 74, 102). In laboratory mice, however, ECTV also exists 
in Europe, but evidence of natural infections is lacking (99). Furthermore, no species 
are known to be the principal host for more than one OPV (74). Thus, antibody 
findings in at least bank voles, which are naturally and experimentally susceptible 
to CPXV (30), are most probably caused by CPXV, as also are possibly antibodies 
in other rodents living in close proximity to bank voles. CPXV, indeed, seems to be 
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extremely ubiquitous in its host spectrum. In addition, its presence in other rodent 
species, both pet and wild rats, has resulted in transmission of the virus to zoo animals 
and humans (24, 154, 182, 205, 344). This study demonstrated that hamsters may 
also be hazardous in this respect, as is probably any pet rodent species.
For the first time, BDV antibodies were detected in wild rodents, namely voles in 
Finland (Table 9). Small numbers of wild rodents have also before and during this 
thesis project been tested without BDV findings (124, 150, 252, 319, 321). Of the 
seropositive individuals detected in this study, three were bank voles and one was a 
root/tundra vole (III and Kinnunen et al. unpublished). BDV could not be detected 
by RT nested PCR or virus isolation in cell cultures from the two tested voles (III and 
Kinnunen et al. unpublished). However, the existence of BDV-specific antibodies in 
rodents was verified by reaction with recombinant BDV antigens and BDV-specific 
peptides or both, by a high antibody affinity to BDV, or repeated seropositive results 
from the live-trapped, free-roaming vole (III).
Table 9. Borna disease virus (BDV) antibodies in Eurasian wild rodents as detected by 








Finland, total 1146 4 0.35 0.095 – 0.89
South 57 1 1.75 0.044 – 9.39 Unpublished
west 530 1 0.19 0.005 – 1.05 III, 
Unpublished
North 130 0 < 0.77 0 – 2.80 III
East 36 0 < 2.8 0 – 9.74 III
Rodents near 
seropositive horses
393 2 0.51 0.062 – 1.83 III
Germany 168 0 < 0.60 0 – 2.17 Unpublished
Buryatia 250 0 < 0.40 0 – 1.46 Unpublished
a 95% confidence intervals, Fisher’s exact test
Despite the recent BDV detection in the bicolored white-toothed shrew (Crocidura 
leucodon) in an endemic region in Switzerland (150, 252), BDV antibodies were not 
found in the 115 insectivores included in this study (data not shown, Kinnunen et al. 
unpublished). The tested shrews belonged to a different species (Sorex araneus) from 
the BDV-positive ones, and did not originate from a targeted, known endemic region, 
unlike the Swiss shrews, but were trapped as a part of other small mammal studies. 
As for rodents, BDV-antibody-positive voles were found in this study, indicating that 
BDV may have distinct hosts in different geographical areas. Apart from western and 
70
north-western Germany, the geographical distribution of bicolored white-toothed 
shrews comprises all classical BDV-endemic regions in central Europe, as well as Israel 
and Turkey (288), but does not comply well to the current BDV distribution data in 
northern Europe (78, 299, 339). In contrast, the bank vole distribution is wider and 
covers all the European countries from which BDV infections have been reported 
(10). Thus, bank voles, together with bicolored white-toothed shrews as reservoirs, 
could explain the geographical pattern of BDV infections at least in Europe.
In Finland, BDV-infected rodents were found sporadically in the south, west and north 
(the latter near to a seropositive horse; III), with similar prevalences when the 95% 
confidence intervals are compared. Rodents from Buryatia and northern, non-BDV-
endemic Germany did not harbour BDV-specific antibodies. whether BDV infected 
wild rodents exist elsewhere in Germany remains to be determined, but this study 
clearly proves that wild voles may exhibit a BDV-specific antibody response indicating 
a natural infection. As is common in natural infections (119, 164, 271), at least three 
times more rodents tested had borderline results, probably indicating an antibody 
level around the IFA detection limit, suggesting that the real BDV prevalence may be 
higher than that interpreted from the obviously BDV-antibody positive rodents.
5.7 opv Dna is r are in roDent organs
Having detected OPV antibodies in wild rodents, PCRs, antibody measurements 
and virus isolation were applied to determine, how commonly the rodents are acutely 
infected, and furthermore, which OPV species are responsible for the antibodies. 
Despite the common OPV antibody findings in Eurasian wild rodents (Table 8), PCRs 
verified OPV DNA infrequently and in low amounts: none of the 156 Buryatian, 
and only 1 of 160 Finnish and 2 of 197 German rodents had OPV DNA with high 
Ct (cycle threshold) values (II). Cell cultures and suckling mice infected with these 
DNA-positive rodent tissues remained virus-negative, further suggesting a low OPV 
amount in the rodents (II). These findings of a high antibody but low DNA/virus 
prevalence demonstrate short-term OPV presence in wild rodents. This parallels 
the common finding of highly avid antibodies in 78% of the studied individuals, 
indicating that the majority of the detected OPV infections were not acute (II). In 
populations studied longitudinally, periods have, indeed, existed with very few acutely 
CPXV-infected rodents (25, 26). 
In comparison to the longevity of the OPV antibody response (173), CPXV itself is 
only present for 1–5 weeks in wild rodent tissues (63, 202). Thus, for virus circulation, 
the transmission has to be effective during the short period of virus excretion or the 
virus must survive in the environment. Indeed, VACV, a correspondingly stabile, close 
relative to CPXV (199), maintains its titre in vaccine baits at ambient temperatures 
for at least one month (237) and endures in storm water for 56–166 days in 4 °C and 
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3–50 days at room temperature. It is also stable on natural products, namely salad, 
bread and sausage, for at least 14 days (97). Furthermore, VACV is stable in the faeces 
of VACV-infected mice at room temperature for 20 days (1). Such viral stability is 
certainly sufficient for CPXV to also be indirectly transmitted to another rodent via 
the environment, which might be especially crucial for viral circulation during cool 
winters when the virus survives best, the rodent population density is low and rodents 
have little direct contact. Thus, transmission cycles may differ according to the season 
and the phase of rodent population dynamics. CPXV transmission probably also differs 
between species (307) and the functional rodent groups possessing different sex and 
maturity statuses: for instance, adults may become infected more commonly in direct 
contact when mating or fighting, and subadults indirectly as well as by horizontal 
transmission. This hypothesised indirect transmission may explain how CPXV can 
exist in populations despite the rarity of active infections. Indirect transmission has 
not been included in the mathematical CPXV transmission models, which have 
shown that the transmission function in the field vole is something between density 
and frequency dependent, but not clearly either of them (292).
In the current study, the overall OPV-PCR prevalence was low in rodents, but acute 
infections could be demonstrated in as many as 25% (3 of 12) of the locations with 
antibody-positive individuals, as evidenced by DNA positivity (II).
5.8 finnish cpx v variant resemBles a russian 
isolate
The OPV PCR amplicons from patients and rodents were sequenced and the sequences 
analysed to clarify the virus species and their molecular epidemiology. From the 
viruses T2000 and E1989, isolated from the Finnish cowpox patients, 948-bp-long, 
identical haemagglutinin (HA) gene sequences were obtained. They matched 96 to 
97% to other CPXV isolates and grouped in a phylogenetic tree, irrespective of the 
method, together with a Russian isolate GR-90 (I; (203)). The Finnish and Russian 
CPXVs formed their own clade, separate from other OPVs.  
These findings have been recently verified and expanded: in addition to the HA 
gene, FIN/T2000 also clusters together with GR-90 according to the sequence of the 
CHOhr gene (132). The same study has furthermore confirmed with several strains 
the finding of this (I) and other work (120, 193): CPXV strains are mainly scattered 
among other OPVs in phylogenetic trees and do not comprise a separate CPXV clade. 
The results of one study, however, provided some evidence of geographical clustering, 
as Finnish and Russian strains, as well as all but one Norwegian and Swedish strains, 
respectively grouped together (132). The close relationship of the Finnish and Russian 
isolates suggests their connected evolutionary histories. 
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Interestingly, the HA sequences of the two cowpox cases 11 years apart, as well as 
the 179-bp-long sequence stretch from the Finnish bank vole, were fully identical to 
each other, indicating that a single CPXV distinct from the other Scandinavian and 
central European isolates may circulate in Finland (I, II). In this respect, the Finnish 
genotypes seem to resemble their British more than their German and Norwegian 
counterparts, because more genetic variation is seen in CPXV genotypes in the latter 
two (132, 172, 214, 220, 243). This variation, but also the close relationship of all 
OPVs was seen when the 132-bp-long OPV sequences from German rodents were 
compared to other available OPV sequences: they were identical to some MPXVs and 
also to a few feline and human CPXV isolates from southern Germany (172), but 
were distinct from most other OPVs, including other German CPXV isolates (II). 
Although more sampling and longer sequences are needed to verify it, these OPV 
sequences from rodents most likely represent CPXV (see “5.6 OPV antibodies are 
common and BDV antibodies occasionally found in Eurasian wild rodents”).
Preliminary data suggest that the Russian GR-90 isolate, which was closest to the 
Finnish isolates, is more pathogenic to mice and rats than the more distant Brighton 
and Turk-74 isolates (203). The possible clinical relevance of the sequence differences 
nevertheless remains to be shown.
5.9 BDv gener ally infects BanK voles w ithout 
pathological changes, major symptoms or an 
antiBoDy response
Newborn bank voles were inoculated i.c. with BDV, observed for 2–8 weeks and 
studied with RT PCRs, (immuno)histology and IFA to determine, whether they 
become infected with BDV and how possible infection manifests. RT PCR and 
immunohistology demonstrated that BDV infects bank vole brains productively (IV). 
Despite the wide spread of the virus and high antigen amount in all 41 infected brains, 
only 7 animals showed focal, mild leptomeningoencephalitis. Moreover, 2 suffered 
from a loss of Purkinje cells (PC) via either necrosis or apoptosis, which was confirmed 
by the detection of active caspase-3 occasionally in PCs (161). The latter two voles were 
symptomatic, expressing either circling and falling or intermittent tremor, while the 
former finding of inflammation did not correlate with any clinical signs. Similar slight 
inflammatory reaction can occasionally be seen in BDV-infected laboratory rodents 
(156, 170, 250, 272, 337), and the loss of PCs is common in neonatally infected rats 
(337). In this study, other voles exhibited no pathological changes. Moreover, the 
majority (31 voles) of the infected and all the control (9) voles remained symptomless; 
the exceptions showed either hyperactivity (6) or neurological symptoms (2) or both 
(2; IV). with this animal number, however, no statistical support existed for the 
correlation of the clinical signs with BDV infection (p = 0.055, MidP exact test). 
Consistent with infected rats and indicative of the potential role of sexual hormones 
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in the pathogenesis (250), female sex was nevertheless a significant (p = 0.0154, 
Mid-P exact test) risk factor for the clinical signs. Locomotor hyperactivity similar 
to some of the voles was observable in BDV-infected MRL/+ mice (268). Although 
immunocompetent rats mostly die of the disease, neonatally infected rats remain 
symptomless ―like the voles― except for slight learning difficulties (250). The fact 
that BDV only exceptionally kills bank voles and mainly causes no clinical signs at all 
is consistent with this species being a possible reservoir. Namely, the reservoir species 
cannot be too severely affected to be able to spread a pathogen.
The pathogenesis of BDV infection probably also depends on the viral strain (145) and 
passage; the virulence seems to increase by passaging in rodents (233, 268). we used 
the 4th rat passage of the laboratory strain He80, referred to as “rat BDV”, originally 
isolated from a Borna-diseased horse but now rodent-adapted (273, 299). This strain 
has previously caused neurological disease in 7 of 8 and encephalitis in all infected 
rats (273). Despite this obvious virulence, the pathology and symptoms in bank voles 
remained negligible or absent. whether further passages in the bank vole would 
increase the virulence in this particular species remains to be shown.
A detectable level of BDV-specific antibodies existed in 41% of the bank voles, 
with antibodies appearing after 3 or more weeks p.i. (IV). This seroconversion time 
correlates well with other experimentally infected rodents: the first i.c.-infected Lewis 
and hybrid rats become seropositive around 10 dpi, whereas black-hooded rats show 
an antibody response only from 35 dpi onwards (108, 147). However, after intranasal 
infection the Lewis rat seroconverts a little later, from 20 dpi onwards (216). All mouse 
strains develop BDV antibodies by 31–49 dpi when infected as weanlings (95, 268). 
Thus, the first antibody finding at 3 weeks p.i. is close to the average for laboratory 
rodents, but the common lack of antibodies even in those tested 6 weeks p.i. (IV) was 
surprising, as all but one of the laboratory rodents had previously mounted an antibody 
response (273). Such differences may relate to the fact that bank voles represent a wild 
animal population most likely having fully functioning immune systems – which is 
not always the case in laboratory-bred rat and mouse colonies (206, 217, 264). The 
ubiquity of antibody-negative but BDV-excreting bank voles should be taken into 
account when interpreting the BDV prevalences of wild rodents (e.g. in III), as when 
estimated based on IFA, the BDV prevalence in bank voles is underestimated (IV). 
5.10 BDv spreaDs neuronally through the BanK 
vole BoDy anD is excreteD 
Having verified that the experimental i.c. BDV infection of the bank vole is 
productive, the infection kinetics was investigated using immunostaining of the vole 
tissues and RT PCRs for urine and faeces. BDV antigens were commonly expressed 
in the peripheral nervous system of the bank vole (IV). For example, axons in nerves 
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innervating the alimentary tract, skeletal muscle, salivary gland, and urinary bladder 
were commonly BDV-positive, and occasionally also a few muscle cells in the urinary 
bladder (Fig. 14), skeletal muscle and heart. The peripheral spread could mainly be 
seen from week 4 p.i. and thereafter, but occasionally already happened 2 weeks p.i. 
Furthermore, BDV RNA was demonstrated in urine (3 voles), faeces (17 voles) or both 
(3 voles) of the infected but not in the control animals, indicating viral excretion after 
centrifugal spread from the CNS. (IV)
Figure 14. Smooth muscle cells of the urinary bladder express BDV N-antigen in nuclei 
and cytoplasma (arrowheads). Immunostaining with mAb Bo-18 1:100. (Photo by courtesy 
of Anja Kipar) 
A peripheral BDV antigen distribution similar to bank voles can occur in i.c.-infected 
rats: newborn or immunoincompetent rats already show a peripheral distribution 
14 dpi, compared to immunocompetent ones 28 dpi (303). In intranasally infected, 
immunocompetent rats, BDV spreads peripherally a little later, 38–60 dpi, although it is 
mainly restricted to their CNS (286). Recently, a peripheral nerve manifestation was also 
demonstrated in i.c.-infected mice, but very late, on 120 dpi (4). The peripheral spread of 
BDV in bank voles, already from 2 weeks p.i. on, more closely resembles that of rats in 
this respect (IV). In addition to the spread in peripheral nerves, laboratory rodents also 
excrete BDV abundantly in urine (103–104 50% tissue culture infective doses/ml, 500–
104 ffu/ml) and less in tears or saliva (216, 273). Likewise, bank voles seemed to excrete 
BDV in urine, as evidenced by the common detection of RNA (17%; IV). Furthermore, 
BDV RNA existed even more commonly in their faeces (54%). Except for somewhat 
confusing PCR amplicons reported from three wild birds (36), no previous reports of 
BDV excretion in faeces have been identified. This result from the present work thus 
significantly widens current knowledge of BDV epidemiology. Like Puumala hantavirus, 
which bank voles excrete (134), BDV is peripherally spread and consecutively excreted in 
bank voles indicating that they could function as a BDV reservoir. 
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5.11 BDv rna is reaDily tr anscriBeD into Dna  
IN VIVO 
Because the genes of ancient bornaviruses have been reverse transcribed and integrated 
into vertebrate genomes as their DNA counterparts (27, 155), the presence of BDV 
DNA in the experimentally BDV-infected bank voles was assessed to determine 
whether this phenomenon occurs nowadays. As many as 66% of the bank voles had 
BDV N DNA in brain tissue, as evidenced by PCR analysis of the extracted DNAs 
and further verification with nuclease treatments: DNAse but not RNAse digestion 
removed the PCR positivity in these assays performed without an RT step (IV). The 
nuclease digestions thus verified that instead of an unspecific amplification of RNA, 
the amplification indeed resulted from DNA. In addition to N DNA, P RNA had also 
been reverse transcribed in vivo as P DNA existed in one animal; borderline results 
were seen in several others. Both N and P DNA were most common at 4 weeks p.i., 
although they could be seen from 2 to 8 weeks p.i. No BDV DNA was detected in 
the mock-inoculated bank voles (IV). These findings parallel, confirm and extend the 
recent observations of BDV N DNA in vertebrates (27, 155): exogenous BDV RNA is 
indeed reverse transcribed into DNA in vivo during infection. Notably, further studies 
will determine whether BDV DNA in experimentally infected bank voles is episomal 
or integrated into chromosomal DNA.
The genome of the bank vole is not yet available to determine whether it contains 
endogenized BDV-like elements (EBL), as in some other rodents (27, 155). EBLs, 
especially the most commonly found EBLN, might play a role in the epidemiology 
of BDV, being possibly advantageous and probably enabling a species to function as a 
reservoir. Based on the BDV literature, it has been hypothesised that species containing 
EBL sequences are more likely to be resistant to a deadly infection than those that do 
not (27). This might result from protection mediated by the expression of indigenous 
BDV N or other components. Indeed, the nucleocapsid components of BDV, i.e. N, 
P and X proteins, convey resistance to BDV infection in cell lines (113). Furthermore, 
specific N epitopes are crucial for sufficient activation of the CD8+ T lymphocytes 
mediating early control of BDV in rats (108). The delicate balance between pathology 
and protection depends on these particular CD8+ T cells (20, 108), thus warranting 
further studies in the light of recent EBLN (and other EBL) findings (27, 155) and 
also sequence determination of possible reservoir species, including the bank vole. 
As an important step on the way to understanding the endogenization of RNA virus 
sequences, the results here demonstrated that the reverse transcription of BDV RNA 
is common in live animals (IV).
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5.12 BDv or a BDv-liK e v irus infects humans  
in finlanD
Serum samples from Finns were collected and assayed for antibodies indicative of 
BDV infection. IFA based on the BDV/He80 strain revealed three antibody-positive 
humans (III). One of them belonged to a panel consisting of veterinarians (138 sera), 
while the two others originated from a serological panel comprising patients suspected 
to have hantavirus infection (361 sera). The antibody positivity of the veterinarian 
was carefully verified: the antibodies were highly avid, recognized multiple antigenic 
BDV peptides and the recombinant BDV P-protein, and the veterinarian again 
tested positive in a blinded assessment with IFA based on a new sample eight years 
afterwards (III and Kinnunen et al. unpublished). Furthermore, the results could be 
reproduced in an independent laboratory. However, no BDV RNA could be detected 
in the veterinarian’s whole blood (Kinnunen et al. unpublished). One of the antibody-
positive individuals was not as thoroughly investigated due to the single low-volume 
sample obtained; therefore, a possibility remains that a BDV-like virus caused these 
serological findings. As the human genome does not contain endogenized BDV P 
sequences (27, 155), the reaction of the two tested BDV-antibody positive human sera 
with BDV P protein excludes the unlikely chance that the reaction in IFA was caused 
by autoantibodies against putatively translated EBLNs (III). Similar continuous BDV-
IFA antibody positivity has recently been seen in psychiatric patients in Germany, but 
updating of the method during the study brought uncertainty to the interpretation of 
the result (142).
This extremely well verified BDV antibody positivity of a human, which reliably 
indicates a human bornavirus infection, is important because of the controversial 
interpretations of the commonness of human BDV infections and the existence of 
human Borna disease (45-48, 89, 90, 105, 106, 190, 191, 194, 227, 248, 271, 284, 298, 
299, 308, 343). Therefore, neither the sample number nor the sensitivity of the assays 
was maximised in this study, but instead, the aim was to find verifiable infections. 
The veterinarian of this study is the best-characterised BDV-seropositive human so 
far, and together with the unambiguous detection of BDV antigen and RNA in a 
few human brain samples (83), it evidences that BDV or a closely-related bornavirus 
infects humans at least occasionally and does not always lead to a disastrous outcome. 
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6. concluDing r em arKs
This thesis shows that the two zoonotic viruses, CPXV and BDV and/or their 
close relatives exist in Finland and infect several mammals, including wild rodents, 
domestic animals and humans (I–III). Furthermore, it extends the knowledge of their 
epidemiology and host spectrum (I–IV) as well as confirms and extends the recently 
found reverse transcription of BDV RNA into DNA in live animals (IV). 
wild rodents, especially the bank vole, are involved in the circulation of CPXV/OPV 
(I, II). Despite the rarity of active CPXV infections in the wild, the risk of zoonotic 
CPXV transmission from rodents exists widely in Eurasia, being occasionally locally 
very high. This represents an infection risk for domestic animals and humans, 
emphasising the importance of rodent control and personal hygiene during and after 
contact with rodents or their excreta. Although we are now better aware of the wide 
geographical distribution of CPXV, the likelihood of acquiring a CPXV infection 
has most probably not changed: the virus has been and will be in wild rodents. The 
individual risk of infection depends on the frequency of contacts with infectious 
hosts, as well as age, sex, and occupation, and probably also on the immune status 
(23). For an individual, the risk is nonetheless low, as the infectious virus is rare and 
not very contagious to humans or domestic animals. However, the severity of the 
outcome in the rare occasions when infection occurs has probably increased. Several 
factors have contributed to this increase: the lack of attenuating immunity caused 
by smallpox vaccinations in younger generations (I), the increased prevalence of 
exacerbating conditions such as allergic and atopic diseases (289), immunosuppressive 
viral infections and treatments, and old age. Consequently, the rare cowpox cases are 
more likely to be grave (I).
Based on the low seroprevalence, BDV is a rarity in Finland (III). However, 2–3 times 
more infected animals exist than can be deduced from the antibody findings alone 
(IV; (119, 164)). Thus, the virus is present and infects humans, horses, cats, dogs, and 
wild rodents, although the majority of infections remain undetected. As the reliable 
diagnosis of BD is not possible intra vitam, proper post mortem samples are needed to 
verify the true clinical relevance of BDV in Finland and elsewhere. During this work, 
the relevant detection methods were established and are ready for future use (III, IV). 
wild voles, especially the bank vole, are involved in the circulation of BDV and 
occasionally loosely associated with clinical cases at least in Finland (III). This research 
proved that bank voles can be productively infected i.c. with BDV (IV) and could 
therefore play a role in BDV epidemiology. However, infection via more natural routes 
should also be demonstrated, although the intranasal and i.c. routes resulted in similar 
symptom and pathological patterns in rats (60), so other routes of inoculation would 
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not necessarily bring more information. BDV is also transmitted from rat to rat (273), 
but not from mouse to mouse (95). whether transmission occurs between bank voles 
(and shrews (252)) remains to be determined, but the general absence of pathological 
and clinical alterations, the common presence of BDV in the periphery resulting in 
excretion in urine and faeces (IV), and the serologically evidenced natural infections 
(III, Kinnunen et al. unpublished) clearly show the potential of bank voles to be a 
BDV reservoir. 
Rodents, including wild rodents and some pets, carry and transmit several rodent-
borne viral zoonoses (roboviruses) in direct or indirect contact with humans: 
hantaviruses such as Puumala, Dobrava, Hantaan, Seoul, Sin Nombre, Laguna 
Negra, Andes, and Black Creek Canal viruses; arenaviruses i.e. lymphocytic 
choriomeningitis virus, Lassa, Machupo, Guanarito, whitewater Arroyo, and Junin 
viruses; encephalomyocarditis picornavirus; Sandfly fever phlebovirus; tanapox virus; 
as well as orthopoxviruses such as MPXV and CPXV (180, 209). In addition, rodents 
are important maintenance hosts in several vector-borne viral zoonoses such as tick-
borne encephalitis (312). This study has revealed that the rodent host range of CPXV/
OPV is wider than thought (II), and in addition has nominated BDV as a candidate 
for the group of roboviruses (III, IV) or, when the recent BDV detection in shrews 
is noted (252), for the newly described (144), wider epidemiological group of rodent- 
and insectivore-borne “rainboviruses”. To better understand the rainboviral nature of 
BDV, infection and transmission experiments should be conducted in shrews.
what else could be the BDV reservoir other than voles and shrews? Because the 
temporal distribution (spring; (90)) does not entirely fit into the epidemiological 
picture of a rainbovirus, especially without incubation periods not shorter than 3 to 
4 months, other mammals should not be too easily excluded from the list of potential 
reservoirs. Bats, in particular, host several related zoonoses of the order Mononegavirales, 
belonging to the families of rhabdo- (lyssaviruses), paramyxo- (Hendra and Nipah 
viruses), and filoviridae (Marburg and Ebola viruses). Plants, arthropods and birds 
have, in addition to mammals, been suggested as remotely possible BDV reservoirs 
(90). Although evidence exists for a plant virus having switched its host to a vertebrate 
(115), it is not very probable that a plant virus would infect mammals. Arthropods, 
including insects, are also probably not to blame, since BDV does not cause a high 
viraemia needed for the transmission of arboviruses, and experimentally BDV-fed 
ticks maintain BDV RNA for only 1–24 days ((275), according to (90)). Furthermore, 
if birds transmitted BDV in addition to ABV, BD would be more common, especially 
in Africa. Naturally, a publication bias might be partially responsible for the apparent 
absence of BD cases there. It is also possible that BDV has complex transmission chains 
involving several host or vector species or both. In addition to searching for BDV in 
new species, the timing of the peaks of primary infections (instead of the peaks of 
clinical cases) and their comparison with and plotting against likely host or vector 
numbers and activities would be crucial for elucidating the obscure transmission cycle 
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of BDV. Longitudinal sampling of susceptible sentinel animals with the detection of 
seroconversion or avidity measurement could be useful in the timing, as long as the 
incubation period is not properly known. whatever the host and vector, it seems clear 
that the BDV transmission cycle needs it/them, as the virus is not easily horizontally 
transmitted, i.e. is not very contagious (75, 321). 
Similarly to BDV, there are hypothetical hosts for CPXV infection other than wild 
rodents. This is an important issue, as in the majority of the human cowpox cases the 
infection source has been unknown (I; (23)). Bats, for example, could be studied for 
CPXV infection, as CPXV is ubiquitous in its host predilection, and the role of the 
dead bat remained obscure in the epidemiology of the cowpox eruption in the Finnish 
girl (See “5.2 CPXV can cause severe infection in unvaccinated atopic children”). 
Furthermore, mosquitoes mechanically transmit another poxvirus, myxoma virus 
(100), so why not OPVs in some cases? Insectivores may also be a reservoir, although 
shrews were seronegative in this study (Kinnunen et al. unpublished). Indeed, an 
intense mole contact probably launched clinical cowpox (203), and OPV antibodies 
have been found in common shrews (183, 317), but further studies are needed to 
elucidate whether they can be natural carriers instead of incidental hosts for CPXV. 
This study, however, demonstrated that CPXV/OPV infects a wide spectrum of rodent 
hosts, namely seven species (II).
According to the serological results, CPXV and BDV are probably under-diagnosed 
in Finland (I, III). Orthopox- and Borna disease virus infections can be effectively 
detected by the established methods (I–IV), and they should be remembered 
as differential diagnoses when encountering animal or human patients showing 
appurtenant symptoms. The declining prevalence of OPV protection, in particular, 
emphasises the need for public awareness, or at least among general practitioners and 
veterinarians. Several epidemiological studies have revealed that veterinarians, even 
more than other professionals working with animals, possess a higher risk to acquire 
a zoonotic infection (17), so they are in a crucial position to detect and consequently 
protect animal owners and themselves from zoonoses. 
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